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Ageing is a highly complexed and regulated interplay between genetic and environ-
mental factors in living organisms. At cellular level, ageing is accompanied with numerous
alternations including changes on protein post-translational modifications (PTMs). Using
quantitative proteomics approach, my phD project aimed at extending our current under-
standing on ageing in the human bone marrow, with a focus on the role of PTMs. The
study stratified human bone marrow into six main sub-populations of cells and examined
changes of the proteome for 59 donors whose age di↵erences span 40 years. Modified pro-
teins were identified through a combination of mass-tolerant and standard database search
method. The analysis showed that PTMs are prevalent in the bone marrow proteome
and displayed cell type dependencies. Proteins di↵erentially modified include glycolytic
proteins and proteins from the heterogeneous nuclear ribonucleoprotein family. Further-
more, analysis on the association between modified proteins and age showed that the level
of modification for the majority of the modified proteins remained stable during ageing.
Acetylated proteins in the haematopoietic progenitor cells were found to bias towards neg-
ative correlation with age, which may be linked with reduced di↵erentiation potential of
the stem cells. Co-regulations of modified proteins during ageing were also observed in the
bone marrow cells, especially in the haematopoietic progenitor cells. The results from this
study could serve as the basis for elucidating the biological mechanisms by which these
PTMs regulate age-associated processes in di↵erent bone marrow derived cells.
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2 Zusammenfassung
Alterung ist ein hoch komplexes und streng reguliertes Zusammenspiel zwischen genetis-
chen und umweltlichen Faktoren in lebenden Organismen. Auf zellula¨rer Ebene ist der
Alterungsprozess begleitet von zahlreichen Modifizierungen, einschliesslich Vera¨nderungen
der posttranslationalen Proteinmodifikationen (PTM). Mit einem quantitativen proteomis-
chen Ansatz ist das Ziel dieser Arbeit unser jetziges Versta¨ndnis von Alterung in der
Knochenmarknische zu erweitern, mit einem Fokus auf die Rolle der PTM. In der folgen-
den Arbeit wird das menschliche Knochenmark in sechs Zellsubpopulationen unterteilt.
Vera¨nderungen des Proteoms wurden fu¨r 59 Spender untersucht, deren Altersunterschied
40 Jahre betra¨gt. Modifizierte Proteine wurden identifiziert durch Kombinierung von
Masse-tolerant und Standard Datenbank Suchmethoden. Die Analyse zeigte, dass PTM
im Knochenmarkproteom weitverbreitet und abha¨ngig vom Zelltyp sind. Zu den unter-
schiedlichen modifizierten Proteinen geho¨ren Proteine der Glykolyse und Proteine der het-
erogenen Ribonukleinfamilie. Zusa¨tzlich zeigte die altersabha¨ngige Assoziierungsanalyse
der modifizierten Proteine, dass das Modifizierungsniveau fu¨r die Mehrheit der modi-
fizierten Proteine wa¨hrend des Alterungsprozesses stabil blieben. Die acetylierten Proteine
in den ha¨matopoetischen Progenitoren korrelierten negativ mit dem Alter, was vielleicht
auf das reduzierte Di↵erenzierungspotential der Stammzellen zuru¨ckzufu¨hren war. Ko-
regulierungen der modifizierten Proteine wa¨hrend des Alterungsprozesses wurden eben-
falls in den Knochenmarkzellen, vor allem aber in den ha¨matopoetischen Progenitoren
beobachtet. Die Ergebnisse dieser Arbeit ko¨nnten als Basis dienen fu¨r die Aufkla¨rung bi-
ologischer Mechanismen, in denen die beschriebenen PTM die altersassoziierten Prozesse
in unterschiedlichen Knochenmarkzellen regulieren.
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3 Abbreviation
ERP erythroid progenitor cell
FACS fluorescent activated cell sorting
FDR false discovery rate
GRA granulocyte progenitor cell
HPLC high-performance liquid chromatography
HPC haematopoietic progenitor cell
hnRNP heteronuclear binding protein
HSC haematopoietic stem cell
LYM lymphoid progenitor cell
LC-MS liquid chromatography-mass spectrometry
MON monocyte progenitor cell
MS mass spectrometry
MS/MS tandem mass spectrometry
MSC mesenchymal stromal cell
PCA principal component analysis
p.p.m parts per million
PSM peptide spectrum matching
PTM post-translational modification
RNA ribonucleic acid
RRM RNA recognition motif
RP-HPLC reverse phase high-performance liquid chromatography
TMT tandem mass tagging
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5 Introduction
5.1 Protein post-translational modifications are crucial for the regulation
of cellular activities
Figure 1: Protein post-translational modifications
and their functions inside cells. Cells regulate var-
ious functions through protein modifications. Pro-
teins can be modified through attachment of various
chemical moieties by controlled process using specific
sets of enzymes. PTMs often have multiple functions
inside the cell. Phosphorylation can change confor-
mation of proteins through allosteric modulation or
change protein activity; lipidation and glycosylation
can direct sub-cellular location of proteins; methyla-
tion and acylation can a↵ect protein-protein interac-
tions whereas ubiquitination can control the lifetime
of proteins. Di↵erent PTMs can crosstalk with each
other on the same protein through competing for the
same amino-acid residue, or residues in close proxim-
ity. Some commonly studied modifications and their
functions are illustrated here. Abbreviations: Ac,
acetyl; Me, methyl; P, phosphate; K, lysine; Ub, ubiq-
uitin. Adapted from [Aebersold and Mann, 2016].
Proteins are the basis of cellular func-
tion of a cell [Alberts, 2008,Lehninger et al.,
2005]. It is an ensemble of polypeptides
synthesized inside cells from amino acids
through covalent linkage of the carboxyl
group of one amino acid to amino group
of another amino acid. The primary struc-
ture of a protein refers to chains of amino
acids in a specific sequence. The order of
the amino acids in the sequence is deter-
mined by the genetic information encoded
in the genome. The backbone chain of a
polypeptide is arranged based on the dis-
tance of hydrogen-bond between the main-
chain peptide groups. This conformational
arrangement gives rise to the secondary
structure of a protein, such as ↵-helixes and
 -sheets. Packing of these secondary struc-
tures via non-specific hydrophobic interac-
tion and specific interaction, such as salt
bridges and disulfide bonds, gives rise to a
three-dimensional conformation. The over-
all three-dimensional conformation is the
tertiary structure of a protein, and is es-
sential for its biological function. The con-
served part of the tertiary structure of a
protein is also known as a protein domain
[Apic et al., 2001]. Protein domains are
present in nearly all proteins (except dis-
ordered proteins, reviewed in [Dyson and
Wright, 2005, Wright and Dyson, 2015]),
and can evolve di↵erently from the rest of
the amino acid sequences [Thornton et al.,
1999]. Duplication and combination of pro-
tein domains create a plethora of protein
structures, which ultimately determine the
17
function of proteins. In addition, many proteins function as assemblies of multiple polypep-
tide chains, which are often referred to as protein subunits. The number and arrangement
of subunits of a multi-unit protein complex is also known as the quaternary structure of
the protein.
Proteins actively participate in all cellular activities, from regulating gene transcrip-
tion, protein translation, to responding to internal and external stimuli. They are multi-
functional molecules: as enzymes they catalyse chemical reactions inside the cellular en-
vironment; as structural proteins they provide mechanical support and enable movement
for cells; as transporters they carry molecules required by cells to locations where they are
needed. Because of their indispensable roles inside cells, several layers of mechanisms have
evolved to regulate proteins [Alberts, 2008]: regulation of protein synthesis and degradation
rates can control the abundance level of proteins; allosteric transitions such as releasing
the catalytic subunit of a protein or cooperative binding of ligands can induce structural
changes of proteins; segregation of proteins in di↵erent cellular compartments is used to
create physical barriers for protein-protein interactions; post-translational modifications
(PTMs) alter the chemical properties of proteins and can modulate activities of proteins.
Protein PTM is regulatory mechanism in addition to gene expression and translational
control [Lehninger et al., 2005,Walsh, 2006]. Inside a cell, PTMs are continuously regu-
lated via endogenous enzymes, or can be acquired from internal and external environment.
Essentially, protein PTMs are chemical modifications to the side-chains of amino acids of
proteins, which can be a reversible or irreversible process. It can occur at any stage during
the lifespan of a protein, to both fine-tune the level of protein expression and modulate pro-
tein function (Figure 1): direct modification such as acetylation and glycosylation during
and after completion of translation a↵ects folding and stability of proteins; phosphorylation
can induce protein conformational change and control protein activity; ubiquitination, the
attachment of a 76-amino-acid polypeptide ubiquitin to a peptide, can target proteins for
proteasomal degradation; lipidation and glycosylation can direct proteins to specific cellu-
lar compartments. There are about 20,000 annotated protein-coding genes in the human
genome, but protein PTMs greatly extend the diversity and complexity of the resulting
human proteome.
PTMs do not act in isolation. The crosstalk between PTMs further increases the
complexity by which protein functions can be regulated. There is an increasing amount
of evidence of extensive crosstalks between di↵erent protein PTMs. Broadly, as suggested
by Hunter, crosstalk between protein PTMs can be classified into positive and negative
interactions [Hunter, 2007]. In the positive form, the initial modification serves as an
activating point for additional PTM or the removal of a second PTM. This is best illustrated
by the phosphorylation-dependent ubiquitination as well as phosphorylation-dependent
18
SUMOylation [Koepp et al., 2001,Nguyen et al., 2013,Hietakangas et al., 2006]. In contrast,
in the negative crosstalk two modifications have a direct competition for the same amino
acid or indirectly inhibit each other through competing in three-dimensional space.
5.2 Mass spectrometry-based proteomics as a mean for studying protein
post-translational modifications
Classical approaches for detecting protein PTM can be traced back to the early struc-
tural and functional studies on individual proteins [Walsh, 2006]. Methods such as Edman
degradation and Bergmann degradation were developed in the early 20th century. Based
on the chemical properties of peptide bonds, those methods can precisely define amino
acid sequence and the position of the amino acid being modified in a peptide sequence.
However, these methods require use of radioactive substances, which is inconvenient and
hazardous. Subsequently, methods such as protein immunno-blotting or enzyme-linked
immunosorbent assay (ELISA) were developed in the mid-20th century and provided al-
ternatives for determining protein PTMs. These methods rely on the binding interactions
between antigen and antibody to identify modified proteins. Accuracy and reproducibility
of these antibody-based assays are highly dependent on the specificity of the antibody.
It still remains as a challenging task nowadays to obtain antibodies with high specificity
for PTMs with small chemical moieties and minimal dependence on flanking amino acid
sequences. Peptide and protein arrays were developed in more recent years. Based on the
specificity of PTM-specific enzymes, the methods have been used to profile binding a nity
and for identification of modification residues [Zhu et al., 2000,Rathert et al., 2008].
The aforementioned biochemical approaches are restricted to studying the structure
and function of a small group of proteins. In contrast, mass spectrometry (MS)-based pro-
teomics methods aim to provide a global understanding of the entire collection of proteins
in a biological sample. Such collection of proteins in a system, whether it is an organism,
a tissue or an organelle, is known as a proteome. Information extracted from proteomics
data is able to provide key insights regarding the dynamics of protein functions of the
chosen biological system. Proteomics-based methods are also suitable for studying protein
PTMs, because any modifications on a protein will lead to a significant mass shift of the
molecule. The change of mass is reflected in the mass spectrometer analysis as the modified
peptide has a di↵erent mass-over-charge (m/z) ratio than that of the unmodified peptide.
The type of modification can be identified and the site of modification can be precisely
located to a single amino acid through analyzing the fragmentation patterns of modified
peptides [Aebersold and Mann, 2016].
Furthermore, proteomics-based methods are able to address some of the bottlenecks
encountered in the biochemical approaches [Zhao and Jensen, 2009]. There are several
advantages of using proteomics-based methods to study protein PTMs. Apart from global
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identification of substrate proteins and the possibility to study the dynamics of protein
PTMs in living systems, MS-based proteomics methods are also highly sensitive due to the
advanced MS instruments. The use of high-performance liquid chromatography (HPLC)
systems and high-resolution mass spectrometers has enabled measurement up to attomolar
level concentration [Forsgard et al., 2010]. Labelling techniques as well as the label-free
quantification methods developed in the last decade further enable us to perform accurate
quantification on abundance and changes of protein PTMs. It is entirely feasible to perform
quantitative analysis on the stoichiometry of a protein modification, i.e. the proportion
of modified proteins versus the unmodified proteins in a biological system. All of these
advantages, coupled with the use of automated robotic platforms and software for data
analysis facilitate the study of PTMs in an unbiased and high throughput manner.
MS-based proteomics methods have been applied by researchers to study various protein
PTMs, such as phosphorylation (phosphoproteome), acetylation (acetylome), methylation
(methylome), ubiquitination (diglycine remnant proteomics) and oxidation (redox pro-
teomics). System-wide PTM studies have consistently identified large numbers of amino
acid sites that are modified. Phosphorylation is the most studied protein PTM using pro-
teomics methods. Recent large scale and in-depth analysis on the human phosphoproteome
has identified from 20,443 to 38,000 phosphorylation sites in human cells [Choudhary and
Mann, 2010,Sharma et al., 2014]. Other modifications such as methylation and acetylation,
in contrast, are less studied and characterized than phosphorylation due to the di culties
in generating specific antibodies that recognize various modification sites at proteome level.
For acetylation, the first proteome-wide analysis in human cells on lysine acetylation re-
vealed 3,600 acetylation sites in Jurkat cells [Choudhary et al., 2009]. Proteomics analysis
on substrates of deacetylase SIRT3 also identified 3,174 acetylation sites in U2O2 cells [Sol
et al., 2012]. Recently, the first high-resolution mass spectrometry analysis on arginine
methylation revealed 8,030 arginine methylation sites within 3,300 human proteins in hu-
man embryonic kidney 293 cells [Larsen et al., 2016]. This high number suggests that the
occurrence of protein methylation may be comparable to that of phosphorylation.
5.3 Protein identification and quantification in mass spectrometry-based
proteomics
Proteins can be studied either as intact molecules or as a collection of peptide forms us-
ing mass spectrometer. The former one, known as top-down proteomics, though technically
and computationally challenging, has the advantage that, in principle, all modifications on
a given protein, can be examined all at the same time [Tran et al., 2011]. The latter one,
known as the bottom-up proteomics, is more widely used by researchers for it is experimen-
tally more tractable and computationally more established. To date, there are three main
approaches used in bottom-up proteomics (Figure 2A): the data-dependent acquisition
(DDA) method aims at unbiasedly profiling the complete proteome; the data-independent
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Figure 2: Protein identification and quantification in bottom-up proteomics. A) bottom-up proteomics
workflow can be divided into three stages, sample preparation, measurement by mass spectrometer and
in silico data analysis. During the sample preparation stage, proteins are extracted from source material
and digested to peptides by sequence-specific enzymes. Often the digested tryptic peptides are fractionated
by chromatography before being injected into the mass spectrometer. Afterwards, fractionated peptides
are electro-sprayed into a mass spectrometer. For mass spectrometry analysis, there are three widely used
methods: the data-dependent acquisition (DDA) methods acquire a full spectrum of peptides at MS1
level, and subsequently collect as many fragmentation spectra at MS2 level as possible; targeted methods
such as selected reaction monitoring (SRM) selectively capture peptides of known mass-to-charge ratio
(m/z) at MS1 level, fragment the captured peptides and then monitor several of the fragmented peptides
over time; the data-independent acquisition(DIA) method such as the sequential window acquisition of
all theoretical fragment-ion spectra (SWATH-MS) is able to select peptides with a range of m/z values.
The selected peptides are fragmented and analyzed in a time-of-flight (TOF) mass spectrometer. Data
analysis of proteomics data usually requires implementation of software suited for each method. For data
obtained from the DDA method, commercial software such as Proteome Discoverer and free software such as
MaxQuant as well as its downstream analysis software Perseus are being widely used. For targeted studies
software such as SkyLine is often used. Studies using DIA method require interpretation of multiplexed
fragment spectra and known fragment spectra from large spectral libraries is often used to help with the
spectra identification. Software such as OpenSWATH has been developed. B) peptide quantification can be
achieved at both MS1 level and MSn level. For MS1 quantification (left), elution profile of precursor ions
from the high-performance liquid chromatography (HPLC) column are integrated, enabling quantitative
comparison of isotopic clusters of the same peptide from two di↵erent mass spectrometer runs. Absolute
quantities can be estimated by adding up peak volumes of all peptides that identify a particular protein
and then determining the proportion to the (known) total proteome mass that has been analysed. Peptides
can also be subjected to label-free quantification at the MS2 level (right). The intensities of fragment-ion
that are unique to a specific peptide are used for quantification, in a way that is analogous to the use of
precursor-ion signal intensities for quantification using MS1-level data. For multiplexed shotgun proteomics,
the reporter ions required for quantification are released at MS2 or MS3 stage during the analysis. For DIA
methods the intensities of fragments that belong to the same precursor ion are extracted to yield a measure
of peptide abundance. Adapted from [Aebersold and Mann, 2016].
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acquisition(DIA) method aims at producing an in-depth, more comprehensive fragmen-
tation information for a given sample [Chapman et al., 2014]; the targeted proteomics
method, which uses selected reaction monitoring (SRM), aims at selectively and repro-
ducibly acquiring peptides of interests [Picotti and Aebersold, 2012].
In general, protein identification in bottom-up proteomics begins with extraction and
purification of proteins of interests, cleaving proteins into short oligopeptides by sequence-
specific enzymes (Figure 2A) [Zhang et al., 2013]. Subsequently, the enzymatically di-
gested peptides are separated to reduce the complexity of the sample for MS. Di↵erent
types of fractionation methods have been developed, including electrophoretic technique-
based fractionation, di↵erential-centrifugation-based fractionation and multi-dimensional
chromatography-based fractionation. Combinations of orthogonal fractionation methods
are often preferred as peptides are separated based on di↵erent physiochemical properties,
hence the complexity of the mixture can be further reduced.
Directly before or after the fractionation, an enrichment step is usually incorporated
to select the modified proteins or peptides from the sample mixture. This step is the
main di↵erence between a generic bottom-up proteomics study and a PTM study. The
enrichment procedures di↵er according to the nature of each modification. Antibody-
based a nity purification is widely used for PTMs with high a nity antibodies available,
such as tyrosine phosphorylation, arginine methylation and lysine acetylation [Zhang et al.,
2009,Ong et al., 2004,Rikova et al., 2007]. A protein PTM can also be chemically modified
in vitro for a nity labelling to enable further a nity purification, as in the case of  -
elimination of O-phosphorylated residues and histidine tag or HA tag of N-terminus of
ubiquitin [Oda et al., 2001,Peng et al., 2003]. Ionic interaction-based enrichment methods
utilise the chemical properties of modification groups. Methods such as immobilized metal
a nity chromatography (IMAC) and titanium dioxide-based solid matrix take advantage
of the negatively charged phosphate group and its ability to interact with ion exchange
beads [Swaney et al., 2009, Pinkse et al., 2004]. Other methods such as strong cation
exchange (SCX) explore the charge-state di↵erences between tryptic phosphopeptides and
tryptic unphosphorylated peptides at low pH for peptide separation [Beausoleil et al., 2004].
After the enrichment step, samples containing the PTM-enriched peptides are introduced
into the vacuum of a mass spectrometer via electro-spray. Information of the mass-over-
charge (m/z) of each peptide on the MS level and MSn levels are collected by the mass
analyser.
The acquired MS/MS spectra are analyzed using software developed according to the
type of mass spectrometry analysis (Figure 2B). The software can deduce the sequence of
the peptide and determine which protein in the protein database or the protein sequence
from a corresponding nucleic acid sequence gives the best match to the spectrum. Protein
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sequences in databases are usually cleaved in silico based on the specificity of the enzyme
used in a given experiment. The masses of the digested peptides are calculated from the
in silico digestion. If the calculated peptide mass matches with the peptide mass acquired
at MS level, the masses of the corresponding fragment ions will be predicted by in silico
fragmentation. The masses of the predicted fragment ions are then compared with the
masses of the acquired fragment ions. For a given spectrum, database search algorithms
also evaluate quality of the matching between the in silico sequences and the experimentally
acquired spectrum. The scores or ratings of the matching are used by software to decide
which predicted peptide sequence is the most likely one among all.
Over the last few decades mass spectrometry has matured from a technique that pro-
duces purely descriptive information on protein to a technique that can generate accurate
and quantitative information that can be used to gain insights on protein abundance and
dynamics. Several quantification strategies have been established for MS-based proteomics.
They can be broadly categorised into two types, the absolute and relative quantification.
Peptide quantification methods for relative quantification can be achieved at MS-level or
MSn-level. The relative quantification of MS-based proteomics can be further divided into
two types, label-free quantification and quantification methods that use isotope labelling
(Figure 3A). In shotgun proteomics studies, there are mainly two techniques that are used
in isotope labelling, namely the metabolic labelling and the chemical labelling.
In metabolic labelling, stable isotopes are incorporated into proteins during protein
synthesis. Cells or organisms used in this method are typically auxotroph for the source
of the isotope used for isotopic labelling [Wu et al., 2004]. Alternatively, stable isotopes
by amino acids in cell culture (SILAC) o↵ers a di↵erent approach, in which an amino acid
deficient culture medium is supplemented with stable isotope enriched amino acids [Ong
et al., 2002]. After a few cell cycles the heavy isotopes will be integrated into the proteome
due to protein turnover. Complete isotopic labelling is often achieved after 5-10 cell cycles.
One main advantage of using metabolic labelling is that the isotopes are introduced during
protein synthesis, hence making it possible to di↵erentiate proteins that are synthesised at
di↵erent stages during an experiment.
Chemical labelling, on the other hand, introduces chemical labels after proteins are
extracted from the source material and purified. Chemical labelling utilises the reactive
groups present on peptides and proteins, and can be achieved at both peptide and pro-
tein levels. The thiol group of the cysteine residues and the primary amine groups are
often the targeted function groups. Linkers containing deuterium atoms can conjugate
with a thiol-specific reactive group to label the free cysteine residues, as exemplified by
isotope coded a nity tags (ICAT) [Gygi et al., 1999]. Labelling on primary amine groups
is often achieved through derivatization of N-hydroxysuccinimide (NHS) chemistry or re-
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Figure 3: Labelling strategies in quantitative proteomics. A) workflows of quantitative proteomics. Step
noted dashed lines shows where the samples are treated separately during experiment whereas steps noted
with solid lines shows where the samples are combined. Labels are introduced at di↵erent stages depending
on the choice of method. In metabolic labelling, samples are labelled and combined at early stage, where as
in chemical labelling samples are labelled and combined at a later stage. Label-free quantification does not
introduce any chemical tag but requires every sample to be processed separately. B) structure of isobaric
mass tags used in chemical labelling. Chemical structure of a generic TMT reagent is shown here: an
amine-reactive group that labels N-terminus and amine group of lysine in peptides, a mass normalization
(balance) group that neutralises the mass di↵erence contributed by reporter ion to ensure overall mass of
tag is the same, and a reporter group that provides information on abundance of peptide upon MS/MS in
individual samples. Cleavage site (indicated with arrow) enables release of reporter ion from the whole tag
upon MS/MS. C) chemical structure of TMT 6-plex reagents with 13C and 15N heavy isotope positions
(asterisks). The tags are isobaric, with a di↵erent distribution of isotopes between the reporter and balance
groups. Adapted from [Rauniyar and Yates III, 2014].
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ductive amination reaction. Di-methyl labelling on amine groups relies on the reaction
between amine with formaldehyde followed by reduction by cyanoborohydride [Hsu et al.,
2003]. Two cycles of these reactions will convert primary amines into tertiary amines with
two methyl groups. Isomers of formaldhyde and cyanoborohydride are used to introduce
stable isotopes. Alternatively, the isobaric mass tagging method o↵ers another choice for
chemical labelling. The isobaric mass tagging methods also rely on the reaction between
the NHS group and the free amine groups on the peptides [Thompson et al., 2003, Ross
et al., 2004, Rauniyar and Yates III, 2014]. Di↵erent from other labelling methods that
aim at creating mass di↵erences between samples, isobaric mass tags introduce chemical
labels that have the identical total mass. The generic structure of an isobaric mass tag
is illustrated in Figure 3B. Generally, those tags are made up by three parts: a reactive
group, a reporter group and a mass balancer group. The total number of isotopes in the
mass reporters and mass balancers remains the same, which ensures that the same peptide
from di↵erentially labelled samples will have the same profile during full MS scan. The
heavy isotopes are distributed between mass tags and mass balancers, therefore the same
peptide from di↵erentially labelled samples can be distinguished from its mass tag profiles
during MS/MS scan (Figure 3C). One unique advantage of isobaric mass tagging method
is that it provides multiplexing capabilities for MS analysis, because the labelling neither
a↵ects the LC separation nor interferes with the MS spectra acquisition. The most com-
mon isobaric mass tagging methods allow multiplexing from 2 samples and can be scaled
up to 10 samples during one MS analysis. In addition, quantification of samples labelled
with isobaric mass tags such as TMT or iTRAQs uses information of the cleaved reporter
ions from MSn spectra. Compared with MS level quantification, MSn level quantification
also gives higher signal-to-noise ratio.
5.4 Mass-tolerant database search provides an alternative way to un-
biasedly profile protein post-translational modifications for shotgun
proteomics data
Protein identification in shotgun proteomics involves handling large volumes of data
collected from MS analysis. The tandem spectra are matched to the corresponding peptides
in the database, which leads to the protein identification. As described in the previous
section, this starts with analysing the mass of the intact enzymatically cleaved peptides
acquired during full MS scan, followed by comparisons of the mass between the predicted
fragment peptide ions and the ones acquired experimentally during MSn scans. Peptide
sequences are assigned through cross-correlation of in silico predicted spectra with those
acquired by MS/MS, using database searching engines, such as SEQUEST and Mascot.
However, it has been noted that the majority of the MS/MS spectra acquired in a typical
shotgun proteomics experiment remain unidentified [Keller et al., 2002]. The underlying
sources for low identification rate in shotgun proteomics is still under debate, but can
be partially explained by unspecific enzymatic activity resulting unexpected cleavage sites,
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Figure 4: Schematic illustration of mass tolerant database method. A) with the standard database search
method intact mass spectrum of a peptide is measured at a mass accuracy of <10 p.p.m. However, often
a peptide carries unknown modifications, which will lead to a change of the detected mass value for both
its precursor peptide ions (dashed lines to solid lines in the spectrum ) and its fragment peptide ions. B)
unexpected modifications on a peptide result in a mass shift of its molecular weight. Standard database
search (green box) is not able to identify such peptide due to its stringent precursor peptide tolerance. In
the mass-tolerant database search method (orange box), algorithms accept a larger deviation of detected
precursor ion mass to theoretical peptide mass, enabling peptide with modification to be identified. The
type of modification could be inferred from the value of the mass deviation, and the site of the modification
could be further deduced from the MSn spectra. Adapted from [Skinner and Kelleher, 2015].
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peptide isoforms not being present in sequence databases as well as unknown protein PTMs.
Proteins are frequently being modified, both in vivo inside cells and in vitro during
sample handling or during measurement. It is estimated that for each unmodified tryptic
peptide detected in a shotgun proteomics study there are on average 8-12 modified forms
of the same peptide [Nielsen et al., 2006]. Normally, the modified peptides and proteins
are studied in a targeted approach by adding specific enzyme inhibitors and including
additional enrichment steps during experiment. However, protein PTMs that are not of
interest in a given study are usually omitted during database search. Spectra originating
from those modified proteins hence remain unidentified. Another major reason underly-
ing the unmatched spectra in shotgun proteomics data is sequence variation not being
present in databases. Underlying reasons contributing to the amino acid sequence varia-
tion include genetic polymorphisms, peptide isoform and also sequencing errors. Sequence
variation from genetic polymorphisms may reduce the lifetime of proteins or cause pro-
tein malfunction. The sequence variation has been investigated through applying de novo
sequencing algorithms and variant peptide databases in proteomics studies.
Many solutions have been created to address those issues in peptide identification. For
example, the peptide sequence tagging methods first infer a short peptide sequence, i.e.
the tag from the tandem mass spectrum, and then search in the database for the complete
peptide sequences that match with the tag as well as the sequence masses flanking it.
The sequence tag methods can identify a peptide in the presence of an unknown PTM or
an amino acid substitution between an entry in the sequence database and the measured
peptide, but this method is limited to spectra where the partial sequences can be derived
either manually or by simple algorithms. A di↵erent approach to address the spectrum
identification problem is to use de novo algorithms. The de novo methods in proteomics
deduce peptide sequences directly from deciphering the spectrum without resourcing to a
sequence database. Open source software such as SeqMS and commercial software such as
Peaks are examples of this technique. However, the accuracy of the de novo methods are
restricted by the accuracy of the MS instruments and the peak intensity of the MS results.
As a result of the rapid improvement on the MS instrumentation, such as the invention
of the Orbitrap mass analyzer, the peptide mass can be determined with an accuracy of up
to sub-p.p.m level. With the wide application of tandem MS/MS, it has become a routine
to obtain such accuracy even for the fragmented peptides. Such high mass accuracy has
enabled researchers to apply a wide tolerance during database search for the precursor ions
and to unbiasedly detect peptides with modifications. Large precursor tolerance searches
have been used in top-down proteomics for protein identification. It has also been used in
bottom-up proteomics and tested on a dataset of around 10,000 peptides [Nielsen et al.,
2006]. Chick et al. adapted the fragment ion mass-tolerant database search method and
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extended it to identify modified proteins from human HEK 293 cell line [Chick et al., 2015].
The principle of the mass-tolerant database search method is illustrated in Figure 4. In
total, 184,000 additional peptides were identified with the mass-tolerant database search
method, resulting in an increase of 46% peptide identification. The modifications that the
newly identified peptides carried were mostly from three sources, endogenous modification,
chemical modifications introduced during experiments, and modification introduced by MS.
It was estimated by Chick et al. that approximately 20% of the newly identified peptides
have modifications that are biologically relevant, such as phosphorylation, methylation,
acetylation as well as many amino acid variations.
5.5 Protein post-translational modifications play a pivotal role in ageing
Proteins are susceptible to numerous changes which occur during ageing, either through
a spontaneous reaction or as a consequence of physiologic or pathologic processes [Rattan
et al., 1992]. Alterations in the rate and fidelity of protein synthesis, modification status
and protein turnover are one of the main features of cellular ageing. Cellular ageing is af-
fected by many intrinsic and extrinsic pathways, which have cross-talks at many di↵erent
levels and are regulated through di↵erent protein modifications [Oh et al., 2014]. Despite
the vast number of protein modifications that proteins can carry, only a few well-known
PTMs have been studied in relation to ageing in individual studies, such as phosphoryla-
tion, methylation, oxidation, ADP-ribosylation and glycation. Those modifications often
occur on proteins that are involved in key cellular processes such as DNA synthesis, protein
synthesis and degradation, energy metabolism, cytoskeletal organisation, and the compo-
nents of the extracellular matrix. Hence, it is di cult to pinpoint any particular pathway
or protein modification as the leading cause of ageing of a cell, though some appear to be
more involved and may be the key regulators at the crossroad of di↵erent pathways.
5.5.1 Phosphorylation
Phosphorylation is one of the most widespread protein PTMs, through which functions
of protein are regulated in response to external and internal stimuli. The dynamic of protein
phosphorylation is actively regulated by protein kinases and phosphatases, two groups of
enzymes that catalyse the transfer of a phosphate group to a substrate and the removal
of a phosphate group from a substrate. Proteins can be phosphorylated on nine amino
acids, namely tyrosine, serine, threonine, cysteine, arginine, lysine, aspartic acid, glutamic
acid and histidine. Among the nine modifiable amino acids, serine, threonine and tyrosine
phosphorylation are predominant in eukaryotic cells [Lehninger et al., 2005]. The cycle of
substrate phosphorylation by kinase and phosphatase starts from binding of ATP to the
active site of a kinase, followed by binding of the substrate to the active site of the kinase.
The   phosphate of ATP is then transferred to serine, threonine or tyrosine on the substrate
from the kinase, and then substrate is released from the kinase. Subsequently, binding
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Figure 5: Interplay between mTOR and longevity pathways through phosphorylation. The serine/threonine
protein kinase mTORC1 is one of the central hubs of several longevity pathways. Activity of mTORC1 is
subjected to various stimulations such as changes of nutrient and hormone levels. The activity of mTORC1
is directly related to longevity as inhibition of mTORC1 by dietary restriction and rapamycin, or by
activation of AMP-activated protein kinase (AMPK) results in increased lifespan in model organisms, such
as S.cerevisiae, C.elegans, D.melanogaster and mice. Inhibition of mTORC1 promotes stress response
transcription factor SKN-1 and leads to an increased lifespan. mTORC1 also negatively regulates longevity-
related phosphoinositide 3-kinase(PI(3)K), protein kinase B and PI(3)K-AKT pathway through inhibition
of insulin receptor substrate 1(IRS-1). In addition, activation of hypoxia-inducible factors 1(HIF-1) by
mTORC1 under hypoxic condition also contributes to longevity through inhibiting FOXO family proteins,
the PI(3)K and AKT mediated transcription factors. The relationship between mTORC2 and mTORC1
remains unclear, but it is known that mTORC2 contributes to longevity through inhibiting FOXO3A via
PI(3)K-AKT pathway. Adapted from [Johnson et al., 2013].
of phosphatase to the phosphorylated substrate catalyses the hydrolysis of a phospho-
monoester, resulting in the removal of the phosphate moiety from the substrate.
Based on the information from human genome, Manning et al. identified in total
518 protein kinases, constituting about 1.7% of all human genes. The human protein
kinases can be categorised into seven major types based on their sequence conservation:
AGC, which includes protein kinase A (PKA), protein kinase G (PKG) and protein kinase
C (PKC) families; CMGC, which includes cyclin-dependent kinases (CDKs), mitogen-
activated protein kinases (MAPKs), glycogen synthase kinase (GSK) and CDK-like ki-
nases; Ca2+/calmodulin-regulated kinases (CAMK), casein kinase 1 family (CK1), re-
lated to yeast sterile kinases (STE) as well as tyrosine kinases and tyrosine kinase-like
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(TKL) [Manning et al., 2002b,Manning et al., 2002a]. Kinases that are serine-threonine
specific can be sub-divided into three classes: the basophilic kinases (e.g. PKA, PKD,
AKT, CAMK2, AURORA and CHK) favour basic residues around the phosphorylation
site; acidophilic kinases (e.g. CKI and CKII) favour acidic residues near modification site;
proline-directed kinases (e.g. Cdks and MAPKs) require a proline residue directly at the
C-terminal to the phosphorylation site [Kreegipuu et al., 1998]. Similarly, based on the
human genome, recently Chen et al. identified a human phosphatome of 264 phosphatases,
representing 1.2% of the human proteome [Chen et al., 2017]. Based on substrate specificity,
phosphatases can be divided into three families: the phosphoprotein phosphatase (PPP)
family (e.g. PP1, PP2A and PP2B) and the metallo-dependent protein phosphatase family
(e.g. PP2C), which are responsible for the dephosphorylation of the majority of phospho-
serine and phospho-threonine; and the protein tyrosine phosphatase (PTP) family, which
dephosphorylate phospho-tyrosine. A subfamily of PTP is able to dephosphorylate all
three phospho-amino acids [Barford et al., 1998,Johnson, 2009].
Signalling pathways regulated by phosphorylation span from but are not limited to
metabolism, proliferation, di↵erentiation, motility, organelle tra cking, membrane trans-
port, immunity and memory formation. One example that has direct implication in ageing
is the serine/threonine-protein kinase mTOR signalling pathway (Figure 5). mTORC1
directly and indirectly regulates the phosphorylation of at least 800 proteins. The mTOR
pathway is activated by growth factors and also in states of high nutrition [Johnson et al.,
2013]. Phosphorylated mTOR complex 1 (mTORC1) up-regulates protein synthesis by
phosphorylating components of mRNA translation and ribosome synthesis machinery. Mu-
tation or RNA interference knockdown of mTOR and direct inhibition of mTOR activity
through rapamycin or calorie restriction (CR) have all been demonstrated to extend the
lifespan of several model organisms, including yeast S.cerevisiae, nematode C.elegans,
fruitfly D.melanogaster and mice [Fabrizio et al., 2001,Vellai et al., 2003,Kapahi et al.,
2004, Harrison et al., 2009, Fontana et al., 2010]. Down-regulation of mTORC1 activity
through activation of AMP-activated protein kinase (AMPK) has also been shown to pro-
mote longevity. In contrast to the mTOR pathway, the AMPK pathway is activated in
response to stress conditions, such as low glucose, hypoxia, ischemia, and heat shock, dur-
ing which the supply of cellular ATP is depleted [Mihaylova and Shaw, 2011,Carling et al.,
2011]. AMPK phosphorylates tuberous sclerosis protein 2 (TSC2), an upstream inhibitor
of mTORC1, resulting in down-regulation of mTORC1 activity. Furthermore, the regu-
latory protein of mTORC1 raptor can also be inactivated through direct phosphorylation
by AMPK [Inoki et al., 2003,Gwinn et al., 2008]. In addition, it has also been reported
that AMPK can extends the lifespan of C.elegans through CREB-regulated transcriptional
coactivator 1 (CRTC-1), which is independent of mTORC1 activity [Mair et al., 2011].
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Figure 6: Intervening longevity pathways through acetylation. Interventions such as calorie restriction(CR),
acetyl-CoA depletion, inhibition of HATs and activation of SIRTs are known to increase lifespan. One specu-
lation is that di↵erent external stimuli for lifespan extension partially act through acetylation (presumably
on histones) to stimulate autophagy. SIRTs induce FOXO-mediated expression of autophagy pathway
components through deacetylating major players of the autophagy induction pathway. In addition, down-
regulation of SIRT1 mediated deacetylation of histone H4K16, serves as an important negative feedback
regulatory loop during autophagy to prevent overstimulation of autophagic flux [Fu¨llgrabe et al., 2013].
The pink writing highlights interventions that are shown to extend life span in model organisms, arrows




Acetylation is a protein PTM of equal importance in cellular ageing. Analogous to
phosphorylation, protein acetylation is also tightly regulated by enzymes. Protein can
be acetylated on its N-terminal residue but also lysine, serine, threonine and cysteine.
Apart from the co-translational acetylation at N-termini, lysine is the most commonly
detected residue for acetylation [Drazic et al., 2016]. Lysine acetyltransferases (KATs)
transfer acetyl group to the substrates, whereas lysine deacetylases (KDACs) remove acetyl
group from the substrates [Roth et al., 2001, Lee and Workman, 2007]. To date, there
are 22 di↵erent KATs from three families identified in human and mouse [Berndsen and
Denu, 2008]. The KATs can be categorised into three types based on their structures,
GCN5, CBP/p300 and MYST11. All KATs utilise acetyl-coenzyme A (acetyl-CoA) as
an essential cofactor to donate an acetyl group to the target lysine residue on substrate.
Acetyl-CoA is required as a cofactor for KAT-mediated lysine acetylation, but can also
acetylate lysine non-enzymatically. For KDACs there have been 18 discovered in human
and mouse so far. The KDACs can be classified into two families with distinct catalytic
mechanisms,Zinc dependent histone deacetylases (HDAC1-11) and nicotinamide adenine
dinucleotide (NAD+) dependent sirtuin deacetylases (SIRT1-7) [Haberland et al., 2009,
Finkel et al., 2009]. The HDACs are predominantly present in nucleus and cytoplasm.
The catalytic activities of HDAC1, HDAC2 and HDAC3 increase upon binding of inositol-
1,4,5,6- tetraphosphate, and are inhibited by metabolites such as D- -hydroxybutyrate
( OHB), L-carnitine, pyruvate and sphingosine-1- phosphate (S1P) [Shimazu et al., 2013,
Huang et al., 2012,Hait et al., 2009,Thangaraju et al., 2009,Millard et al., 2013]. The SIRT
family deacetylases are mostly detected in nucleus. Deacetylation by SIRTs is dependent on
its co-enyzme NAD+ [Imai et al., 2000]. Sirtuin-catalysed deacetylation converts NAD+ to
nicotinamide, and conversely nicotinamide acts as a competitive inhibitor for the catalytic
activities of SIRTs [Bitterman et al., 2002,Avalos et al., 2005].
Studies on protein acetylation have suggested that KATs and KDACs play multiple
roles in regulating ageing process (Figure 6). Using HAT inhibitor spermidine or reducing
the HAT co-factor acetyl-CoA, it has been demonstrated that reduction of global histone
acetylation increases lifespan in D.melanogaster, C.elegans and mammalian cells, and
also increase resistance to stress in S.cerevisiae and mammalian cells [Eisenberg et al.,
2009,Eisenberg et al., 2014]. Similarly, deletion genes encoding HDACs that remove histone
acetylation markers such as H3K56Ac, results in a shortened life span in S.cerevisiae. In
mammalian cells, changes in acetylation status often induce autophagy, which modulates
longevity [Marin˜o et al., 2014]. It is known that autophagy-induced lifespan extension is
often mediated through AMPK and TOR pathways [Gelino and Hansen, 2012, Morselli
et al., 2010]. Changes of acetylation induce autophagy but increase lifespan independently
of mTORC1 and p53, as it has been observed that SIRT1 was not required for the induction
of autophagy by rapamycin or p53 inhibition both in mammalian cells and in C.elegans.
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This suggests that acetylation a↵ects di↵erent autophagy components than mTORC1 and
p53 for the extension of lifespan. In agreement with the observations, it has been found
that induction of autophagy through restricted level of acetyl-CoA alone can also extend
lifespan in D.melanogaster. It has been found that SIRT1 stimulates autophagy through
deacetylating key components of the autophagy pathway, such as autophagy-related protein
5 (Atg5), 7 and 8 [Ng and Tang, 2013]. The nucleus SIRT1 also induces FOXO-mediated
expression of autophagy pathway components. In addition, histone acetylation is suggested
to be involved in the inhibition of autophagy when a high concentration of acetyl-CoA is
present [Marin˜o et al., 2014]. Down-regulation of SIRT1 mediated deacetylation of histone
H4K16 provides a negative feedback regulatory loop, which prevents overstimulation of
autophagy [Fu¨llgrabe et al., 2013].
5.5.3 Methylation
Methylation is another common PTM that has wide implications for protein func-
tions. Recent proteomics studies on human cells by Larsen et al. estimated that protein
methylation to be as wide-spread as phosphorylation and ubiquitination [Larsen et al.,
2016]. Protein methylation mostly occurs on arginine and lysine residues [Comb et al.,
1966,Aletta et al., 1998]. Protein methyltransferases are enzymes that catalyse the transfer
of methyl group to substrate proteins. They are classified into two types, lysine methyl-
transferases (PKMTs) and arginine methyltrasferases (PRMTs). PKMTs can be further
divided into two di↵erent groups, the SET-domain protein methyltransferase superfamily,
including proteins known to methylate histones such as SUV39, SET1, SET2, EZ, RIZ, and
non-SET-domain proteins, such as DOT1-like histone H3K79 methyltransferase (DOT1L),
methyltransferase-like 10 (METTL10) and METTL21A [Feng et al., 2002,Hamamoto et al.,
2015]. The SET-domain proteins transfer a methyl group from S-adenosyl-L-methionine
(AdoMet) to the amino group of a lysine residue on the histone or other substrates. The
non-SET-domain protein catalyse the transfer of methyl group in a similar mechanism de-
spite lacking a SET domain. For arginine methylation, the PRMTs catalyze the transfer of
a methyl group from S-adenosylmethionine (SAM) to the guanidino nitrogen atoms of argi-
nine for the formation of methylarginine. Based on structure, human PRMTs are classified
in three groups, type I, II and III PRMTs [Blanc and Richard, 2017]. The type I (PRMT1,
PRMT3, PRMT4 and PRMT6 and PRMT8) and type II enzymes (PRMT5 and PRMT9)
all have central cavities and two active sites opposing each other to form a homodimer
structure [Zhang and Cheng, 2003,Jain et al., 2016]. In contrast, type III enzyme PRMT7
does not possess a central cavity and acts as a monomer [Jain et al., 2016,Debler et al.,
2016]. Both the type I and II PRMTs catalyse the formation of monomethyl arginine. In
addition, the type I PRMTs can further add a methyl group to the monomethyl arginine
to form an asymmetric dimethyl arginine whereas the type II enzymes forms an symmet-
ric dimethyl arginine. Type III enzyme PRMT7 forms monomethylarginine. The added
methyl groups can be removed by protein demethylases such as lysine-specific demethy-
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lase 1 (LSD1 or KDM1A) and Jumonji C (JmjC)-domain-containing proteins [Shi et al.,
2004,Tsukada et al., 2006].
Protein lysine methylation is known for its regulatory functions in gene transcription as
PKMTs are the main enzymes catalyse histone methylation, whereas arginine methylation
has been reported to regulate cellular activities such as RNA processing, gene transcription,
DNA damage repair, and signal transduction [Hamamoto et al., 2004]. Enzymes regulating
protein methylation and demethylation have been implicated in disease progression, such
as deregulation of PKMTs (SUV39H1 and EZH2) in tumorgenesis of lung and prostate
cancer [Hamamoto et al., 2015].
Among the substrates targeted by methyltransferases and demethyases, histones are
most frequently linked to ageing. Histone methylation is known to have an impact on
longevity and this epigenetic trait is shown to be heritable in C.elegans [Greer et al.,
2011]. Studies in model organisms showed an increase of activating histone methylation
sites and a corresponding decrease in repressive histone marks during ageing, suggesting a
global alteration of chromatin structure during the ageing process. In addition to histone
methylation, which is mostly regulated by PKMTs on lysines, it is also known that arginine
methylation plays a role in delaying ageing. Arginine methylation is required to maintain
the di↵erentiation capacity of various stem cells. The loss of PRMTs in transgenic mice,
including PRMT1, CARM1, PRMT5, PRMT6 and PRMT7, have all been linked to cellular
senescence and premature ageing phenotype [Gao et al., 2016,Pang et al., 2013,Banasavadi-
Siddegowda et al., 2016,Neault et al., 2012,Blanc et al., 2016]. PRMTs are also associated
with ageing for their function in cellular senescence. In muscle stem cells and hematopoietic
stem cells, loss of arginine methylation is linked to reduced di↵erentiation capacity and
diminished stem cell population, implying a link between epigenetic modulation of arginine
methylation and ageing [Blanc and Richard, 2017,Liu et al., 2015].
5.6 Bone marrow as a critical component of the immune system and its
role in ageing
The immune system is a multi-layered defence mechanism intensely shaped by evolu-
tionary forces in the organism’s defence against pathogenic factors. In human, the immune
system is an interactive network composed of lymphoid organs, immune cells, various hu-
moral factors and cytokines. There are two types of immune responses, the innate and
the adaptive. During an event of pathogenic invasion, elements that comprise the innate
immune system, namely the neutrophils, monocytes, macrophages and the complement
system will provide rapid response. In contrast, the adaptive immune system takes days
and weeks to develop and respond. The adaptive immune response involves antigen-specific
reactions mediated by T lymphocytes (T cells) and B lymphocytes (B cells). As the major
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Figure 7: Bone marrow microenvironment and its composition. A) the bone marrow microenvironment
is composed of parenchyma and stroma. The parenchyma contains haematopoietic stem cells (HSCs)
and progenitor cells at various di↵erentiation stages. The HSCs are found to preferentially locate near the
sinusoids. The stroma contains MSCs, which promote maintenance of HSCs by secreting soluble factors such
as SCF64, CXCL12. Perivascular part of the stroma contains cells including CXCL12-abundant reticular
(CAR) cells, which are destined to form bone in vivo. Other cells and structures that inhabit the bone
marrow niche include sympathetic nerves, non-myelinating Schwann cells and osteoclasts. Osteoblasts
do not directly promote the maintenance of HSCs but promote the maintenance and di↵erentiation of
subpopulations of lymphoid progenitors by secreting factors such as CXCL12. Early lymphoid restricted
progenitors thus reside in an endosteal niche that is spatially and cellularly distinct from HSCs. Adapted
from [Morrison and Scadden, 2014]. B) classical model of haematopoiesis predicts a dichotomous lineage
restriction of multi-potent haematopoietic stem cell to lymphoid stem cell and common myeloid stem cell.
The myeloid and lymphoid cells will further di↵erentiate into various immune cells. The precursor cells of
erythrocytes, granulocytes, monocytes, thrombocytes, and lymphocytes are all formed in the bone marrow,
whereas the matured cells circulate in the blood stream. In addition, the bone marrow MSCs are precursor
cells that di↵erentiate to constitute the non-haematopoietic part of the bone marrow. Progenitor cells of
MSCs include osteocyte, chondrocyte and adipocyte.
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Figure 8: E↵ects of ageing on lymphocyte production and distribution of cells in secondary lymphoid
tissues. Several events contribute to the decreased number of immune cells and the declined of function of
adaptive immune system during ageing. Production of T cell is decreased as a result of thymic involution,
which entails decreased mass of thymic cortical and medullary and an increased amount of fat. Production
of B cells is also likely to decrease with age as content of haematopoietic bone marrow reduces with age.
In addition, in the elderly population it is often observed that the CD8+ T cells clonally expand their
population, resulting in a skewed proportion of T-cell repertoire and an increased number of terminally
di↵erentiated memory CD8+ T cells in peripheral blood. Adapted from [Dorshkind et al., 2009].
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players in the cell-mediated immunity, both T cells and B cells are created inside the pri-
mary lymphoid organ, the bone marrow through di↵erentiation of the haematopoietic stem
cells (HSCs). In adults, upon di↵erentiation from HSCs into lymphoid precursor cells, the
lymphoid precursor cells migrate from the bone marrow to the thymus, where they com-
plete the di↵erentiation process and become mature T cells. In contrast, the precursor B
cells are matured inside the bone marrow.
The human bone marrow is an haematopoietic organ composed of cortical and trabecular
bone, cartilage, haematopoietic and connective tissues (Figure 7A) [Zhao et al., 2012,
Morrison and Scadden, 2014]. Transcriptomics data shows that 58% of all human proteins
are expressed in the bone marrow. In total 300 of those genes have elevated expression
levels (at least five-fold) in bone marrow compared to other tissue types [Uhle´n et al.,
2015]. The parenchyma part of bone marrow harbours HSCs and various blood cells.
As the most primitive cell type inside bone marrow, the HSCs di↵erentiate into stem
cells of the myeloid and lymphoid lineages. The myeloid and lymphoid stem cells will
further di↵erentiate and eventually become blood cells and platelets. The precursor cells
of erythrocytes, granulocytes, monocytes, thrombocytes, and lymphocytes are all formed
in the bone marrow. Therefore, the bone marrow contains blood cells in various stages
(Figure 7B). On the other hand, stroma is the non-haematopoietic structural tissue of the
bone marrow. The stroma does not directly participate in haematopoiesis but instead it
provides the microenvironment and growth factors needed during haematopoiesis of the
parenchymal cells. The stroma consists of mesenchymal stromal cells (MSCs) and various
multi-potent cells, including osteoblasts, adipocytes, fibroblasts and endothelial cells. The
bone marrow MSCs are the precursor cells that di↵erentiate into various progenitor cell
types, which constitute the bone marrow niche. In addition, the bone marrow MSCs
are also known to have immunoregulatory functions [Chen et al., 2006]. They are able
to modulate immune responses through direct interactions with di↵erent immune cells as
well as through secreting soluble factors. In vitro, the bone marrow MSCs have shown
to inhibit proliferation of T cells, B cells, natural killer (NK) cells and dendritic cells
(DCs) [Devine et al., 2003,Ghannam et al., 2010,P De Miguel et al., 2012]. They are also
able to inhibit functions of immune cells, such as secretion of cytokines and antibodies as
well as antigen presentation. It has been suggested that the bone marrow MSCs function
as immune modulators. They suppress the functions of the immune cells and play a role
in transplantation tolerance, autoimmunity and cancer metastasis [Chen et al., 2006].
The immune system undergoes a series of alternations upon ageing, a↵ecting the health
condition and survival of the individual [Simon et al., 2015]. Overall upon ageing, the im-
mune system displays declined fidelity and e ciency, the feature known as immunosenes-
cence [Goronzy and Weyand, 2013,Oishi and Manabe, 2016]. For the adaptive immunity,
the number of peripheral B cells does not decline with age but the number of T cells in-
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creases upon ageing [Weiskopf et al., 2009,Fu¨lo¨p et al., 2013]. During ageing, deterioration
of the ability to establish immunological memory in response to new antigens accompa-
nied by decreased production of cytokines by CD4 and CD8 T cells was also observed
(Figure 8) [Walker and Slifka, 2010,Akue et al., 2012]. The innate immunity also expe-
riences profound changes upon ageing. The lineage di↵erentiation in haematopoiesis has
been reported to skew towards myeloid populations in the elderly [Cho et al., 2008,Tang
et al., 2013, Geiger et al., 2013]. Furthermore, the levels of pro-inflammatory cytokines
IL-1 , IL-6, IL-18 and TNF↵ in the blood circulation were reported to increase in the aged
immune system [Van Duin et al., 2007, Franceschi et al., 2007]. In the elderly persistent
inflammation contributes to a chronic low-grade inflammation, which leads to the further
development of other conditions such as cancer, cardiovascular disease, stroke, Alzheimer’s
disease and dementia [Chung et al., 2009,Childs et al., 2015,Oishi and Manabe, 2016]. In
addition to the changes to the immune cells, immunosenescence may also evoke changes in
the microenvironment. It has been suggested that interactions between immune cells and
senescent non-immune cells with gut microbiota may play a role in immunosenescence [Ho-
tamisligil, 2017, Smith et al., 2017]. Thus, intertwined mechanisms at cellular, tissue and
systemic levels contribute together to the development of immunosenescence during ageing.
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6 Aim and Study Design
6.1 Aim of the study
Ageing, which can be broadly defined as a progressive decline of functions of a living
organism, is the results of a highly complex and regulated interplay between genetic and en-
vironmental factors. It involves dysfunctions at the cellular, tissue and organ levels [Lo´pez-
Ot´ın et al., 2016]. Several candidate hallmarks for the primary causes of ageing, the antag-
onistic and integrative responses to ageing have been discussed and reviewed [Lo´pez-Ot´ın
et al., 2013]. They are, DNA damage, telomere erosion, epigenetic drift, loss of proteostasis,
stem cell exhaustion, altered intercellular communication and deregulated nutrient sensing.
Due to its complex nature, there are still numerous questions that need to be addressed,
in order to reach a comprehensive understanding on this biological phenomena. Advanced
technologies such as next-generation sequencing accompanied with in vitro experiments
and animal model studies can elucidate on the genetic and epigenetic changes associated
with ageing. In addition to focusing on individual gene, protein or pathway, systematic
approaches will provide integral insights on the mechanisms that link di↵erent biological
processes to ageing. Using the human bone marrow as a model system, my PhD project
aims at extending our current understanding of ageing in the human system. In particu-
lar, the role of protein PTMs in ageing in di↵erent human bone marrow derived cells are
examined. Questions specifically asked are:
• How is the human bone marrow proteome modified?
• Which proteins or modifications are di↵erentially regulated within the human bone
marrow across di↵erent cell types?
• Is there any proteins and modifications that are associated with advanced age?
• Is there any proteins or modifications that are di↵erentially regulated within the
human bone marrow during ageing?
6.2 Study design
To address the questions, six di↵erent cell types residing in the bone marrow, namely
haematopoietic progenitors (HPCs), lymphoid progenitors (LYMs), monocyte progenitors
(MONs), erythroid progenitors (ERPs), granulocyte progenitors (GRAs) and mesenchymal
stromal cells (MSCs) were analysed (Figure 9). Cells were taken from donated bone mar-
row aspirate at Heidelberg University Hospital under the approval by the ethics commit-
tee. Di↵erent cell populations were obtained via fluorescent activated cell sorting (FACS)
using antibodies against di↵erent haematopoietic lineage markers. In total, 59 healthy
donors were recruited for this study. The ages of the donors are in between 20 to 60.
High-resolution liquid-chromatography coupled tandem mass spectrometry(LC-MS/MS)
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was used to measure the proteome of the bone marrow niche. All samples were labelled
with tandem mass tagging (TMT) for quantitative comparisons between individuals in the
ageing analysis.
The acquired MS data was analysed using both standard and mass-tolerant database
search methods. The standard shotgun proteomic database search method uses narrow
mass tolerance windows for both precursor ions (MS1 search window) and fragment ions
(MS2 search window). The narrow mass tolerance window ensures e cient and accurate
prediction of the identity of the peptide and consequently the identity of the protein. Hence
the standard database search method was employed to identify unmodified peptides and
proteins. On the other hand, the mass-tolerant database search method uses an extended
mass tolerance window for precursor ions and a narrow mass tolerance window for frag-
ment ions. The increased precursor ion search window allows spectrum from peptides with
unknown PTMs to be analyzed. Therefore, the mass-tolerant data base search was applied
to discover abundant PTMs within the human bone marrow proteome. Subsequently, for
confident identification of modified peptides, the standard database search was performed
again, including PTM identified from mass-tolerant searches in the search parameter. This
combined strategy of standard and mass-tolerant database search methods hence enabled
me to unbiasedly capture abundant PTMs inside the human bone marrow as well as iden-
tify proteins with those modifications. Together with the quantitative labelling method,
proteins di↵erentially modified during ageing across all six cell types were analysed.
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Figure 9: Project design. Cells were obtained from donated bone marrow material. Haematopoietic lineage
cells were sorted via fluorescent activated cell sorting (FACS) whereas mesenchymal stromal cells were
separated by in vitro seeding. Cells were lysed, digested and labelled with TMT-6plex labels. Cell-type
specific internal standards were labelled with TMT 126, whereas age-randomised samples were labelled with
TMT 127 to TMT 131. TMT sample mixtures were fractionated using orthogonal HPLC separation and
measured by tandem MS/MS. Data was analysed using the combined mass-tolerant and standard database
searches. Mass-tolerant search was applied to identify spectra with significant mass shifts, with which
prominent protein PTMs were deduced. Proteins with modifications were then identified using standard
database searches including PTMs of interests in the dynamic search parameter. Modified proteins were
validated in-silico and investigated for di↵erences across cell types as well as age-associated changes in
human bone marrow. Abbreviations: HPC, haematopoietic progenitor cell; LYM, lymphoid progenitor
cell; MON, monocyte progenitor cell; ERP, erythroid progenitor cell; GRA, granulocyte progenitor cell;
MSC, mesenchymal stromal cell
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7 Profile Protein Post-translational Modifications Inside Hu-
man Bone Marrow With Mass-tolerant Search Method
7.1 Summary
The project aimed at charting the human bone marrow proteome, and extending the
understanding on ageing with the human bone marrow as a model. For the project, I
performed the proteomics experiments and acquired the dataset. I further used a com-
bined strategy to use both standard and mass-tolerant database searches to identify the
frequently occurred PTMs in the human bone marrow proteome. Proteins with the fre-
quently occurred PTMs were then identified and compared. In this chapter, overview of
the human bone marrow proteome are presented. Optimisation steps for the parameters
used in the mass-tolerant database searches are presented next, followed by the profiles of
the most frequent occurred PTMs of the human bone marrow proteome. Interplay and
cross-talks between di↵erent PTMs inside the human bone marrow are also analysed.
7.2 Result
7.2.1 Standard database search identified over half of the proteins from the
expressed genes in the human bone marrow
In this study, the proteome of the human bone marrow was analysed using tandem
mass spectrometry, coupled with TMT tandem tagging as quantification strategy. To
resolve the human bone marrow proteome, bone marrow material was collected from 59
healthy donors with ages between 20 to 60 (Supplementary Figure 1). Cells from six
major cell types inside the human bone marrow were analyzed. The six cell types analysed
were haematopoietic progenitor cell (HPC), lymphoid progenitor cell (LYM), monocyte
progenitor cell (MON), erythroid progenitor cell (ERP), granulocyte progenitor cell (GRA)
and mesenchymal stromal cell (MSC). Cells from the haematopoietic lineage were isolated
using fluorescence-activated cell sorting (FACS) whereas MSCs were obtained via in-vitro
culture. Proteins obtained from the cell lysate were digested to tryptic peptides, which
were further fractionated with orthogonal liquid-chromatography and measured by liquid
chromatography-tandem mass spectrometry (LC-MS/MS) with higher energy collisional
dissociation (HCD) in a quadrupole Orbitrap mass spectrometer.
The proteome of the six bone marrow derived cell types were analyzed using both stan-
dard and mass-tolerant database search methods. The standard database search method
(with 15ppm precursor ion tolerance) was used to identify the unmodified proteins within
the human bone marrow proteome. With a 1% protein false discovery rate (FDR), 7,322
proteins of the human bone marrow proteome were captured (Figure 10A). The number
of the identified proteins represented 65% of the bone marrow transcriptome annotated
in the Human Protein Atlas [Uhle´n et al., 2015, Andersson et al., 2014]. Notably there
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Figure 10: Overview of the human bone marrow proteome. A) 6,526 unmodified proteins from six di↵erent
cell types were identified in this proteomic dataset, representing 65% of the bone marrow-expressed genes.
The majority of the 796 proteins not detected in previous bone marrow transcriptomics and proteomics
dataset, were extra-cellular matrix proteins expressed at high level in MSC population. B) in total, 2,577
proteins were identified in all six cell types, representing 35% of the bone marrow protein content. 1,695
proteins, 23% of the bone marrow proteome, were detected in only one cell types. C) the number of proteins
that can be quantified for ERPs, GRAs, HPCs, LYMs, MONs and MSCs were 2,994, 3,229, 3,911, 4,451,
4,385 and 5,283, respectively. The number of quantified proteins represented 82 to 89% of the proteins
identified in the study. The quantified proteins were analyzed for age-associated changes in the protein
PTM in the human bone marrow. D) proteins identified in the study were from a fraction of the entire
MS dataset. Using standard database search alone, 8 to 21% of the spectrum of the human bone marrow
proteome was successfully mapped to protein database.
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was a small set of proteins (n=796) within the human bone marrow that have not been
previously identified in transcriptomics analysis. The 796 proteins are predominantly ex-
tracellular matrix proteins and membrane associated proteins, the majority of which were
highly expressed in the MSC population. This presumably explains the discrepancy in
the identification between ours and the previous study as MSC was not included in the
study by Andersson et al.. For the individual cell types, 3,588 proteins were detected in
ERPs, 3,917 proteins in GRAs, 4,568 proteins in LYMs, 5,077 proteins in MONs, 5,110
proteins in HPCs and 5,907 proteins in MSCs. 35% of the identified bone marrow proteins
(n =2,577) belongs the core-set of the bone marrow proteome, i.e. proteins expressed in
all six cell types, whereas 23% of the bone marrow proteome were detected in only one cell
type (Figure 10B).
Depending on the cell type, 82 to 89% of the identified proteins were quantified based
on the TMT 6-plex labels (Figure 10C). There were 2,994 proteins in ERPs, 3,229 proteins
in GRAs, 3,911 proteins in HPCs, 4,451 proteins in LYMs, 4,385 proteins in MONs and
5,283 proteins in MSCs quantified based on TMT tandem mass tags. Proteins that can be
quantified were used for quantitative comparisons of protein PTM levels across di↵erent
ages in Section 9.
7.2.2 Unbiased identification of proteins with modifications in human bone
marrow with mass-tolerant database search
The standard database search method successfully matched less than one fifth of the
spectrum collected in this study (Figure 10D). Many of the unidentified spectra may orig-
inate from modified peptides, hence the mass-tolerant database search method was ap-
plied to uncover the modified fraction of the bone marrow proteome. The principle of
mass-tolerant database search method is illustrated in Figure 4. In short, mass-tolerant
database search method increases precursor ion tolerance during database search, which
allows the search algorithm to be more tolerant to mass di↵erences during peptide assign-
ment. Therefore, peptides with unknown modification could be identified by comparing
the mass shift of spectrum to the mass di↵erence induced by known PTMs.
In order to unbiasedly uncover PTMs enriched inside human bone marrow, I first
examined the range of the mass di↵erences induced by known protein PTMs in Unimod.
Unimod is a public domain database dedicated for protein modifications for mass spectrom-
etry application, containing accurate values of mass di↵erences introduced by natural and
artificial modifications. 85% of the modifications annotated in Unimod database induce
changes of mass value below 500 Da (Figure 11A). Since the majority of the known protein
PTMs induce mass changes below 500Da, five di↵erent precursor ion tolerance windows
(i.e.100 Da, 200 Da, 300 Da, 400 Da and 500 Da) were applied to capture as many potential
modifications inside the bone marrow as possible. Noted that when a spectra was identified
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Figure 11: Identification of post-translational modifications enriched in human bone marrow proteome. A,
85% of all protein PTMs annotated in Unimod database introduce a mass shift less than 500 Da; B, the
number of spectra matches to Uniprot database increased with precursor ion mass tolerance increasing
from 100 Da to 500 Da; C, number of identified mass shift peaks increased with larger precursor ion mass
tolerances, but the number of protein PTMs can be deduced through correlation with Unimod database
saturated when the precursor ion mass tolerance reach 400 Da to 500 Da; D, 261 mass shift peaks were
identified from the bone marrow proteome. 45 % of the mass shift peaks could be induced by protein
modifications, including 26 protein PTMs and 84 amino acid (AA) substitutions.
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Figure 12: Deducing protein PTMs from the mass shift of spectrum. An example to demonstrate the peak
calling of peptide mass shift and deduction of protein PTM from the peptide mass shift. The result of one
TMT-6plex experiment from MSC using mass tolerant search with 500 Da precursor ion tolerance window is
presented. Spectrum were clustered according to the mass shifts, i.e. the di↵erence between the mass of the
peptide captured by mass analyzer in mass spectrometer and the molecular weight of the peptide predicted
to match the spectrum). Mass shift peaks were called out using Gaussian kernel function. Between the
mass shift window -16.80 Da and -18.20 Da two distinct mass shift peaks were identified. The median of
the mass shift of all spectrum within the two peaks was assigned as the mass shift values of the peaks.
Given 0.01 Da mass deviation, known protein PTMs that are within the range of 0.01 Da of the mass shifts
is dehydrated phosphorylation, which induces a molecular weight change of -18.0153 Da.
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di↵erently in standard and mass-tolerant database searches, only the identification result
obtained from the standard database search was kept.
The number of spectrum matched to a peptide sequence in a protein database is
known as peptide spectrum match (PSM). The number of PSM increased due to reduced
stringency to the accuracy of the precursor ion mass during peptide spectrum matching
(Figure 11B). For all six cell types, 8% to 23% additional spectrum were matched to protein
database entries using mass-tolerant searches in comparison to the number of PSMs in
standard database searches, suggesting many of the unassigned spectra are of good quality
and may carry unknown modifications.
To determine the composition of the modified peptides within the dataset, peptides
with mass shifts were collected and collated based on their mass shift values (bins of 0.01
Da) (Figure 12).The mass shift of a spectra is the di↵erence between the molecular weight
of the peptide calculated by the database search algorithm and that measured by the mass
spectrometer. A collection of peptides with the same mass shift are most likely carrying the
same PTM. Therefore, peaks were called from the spectrum with mass shifts. The average
mass shift value of all spectrum within each peak was assigned as the mass shift value of
the peak. The total number of peaks that passed the cuto↵ increased with precursor ion
tolerance window size(Figure 11C).
To identify the modifications, the mass shift values of the peaks were compared to the
mass changes induced by protein PTMs annotated in Unimod database. Two criteria were
applied: 1) the mass di↵erence between the mass shift value of a given mass shift peak is
within 0.01 Da of the mass di↵erence induced by the modification in Unimod database; and
2) for the peptides belonging to a given mass shift peak, the amino acid required for the
known modification should be enriched in the peptide sequences. Similar to the number
of peptide with mass shift, the number of matched Unimod modifications increased with
precursor tolerance window size (Figure 11C). The most frequently occurred protein PTMs
were summarized in Table 1. Modifications captured in all six cell types include various
forms of oxidation, phosphorylation and methylation. Modifications detected in specific
cell types were quinone modification (in ERPs) and glycosylation(in MSCs and GRAs). In
total, there were 119 modifications deduced from the entire dataset, 26 of which are known
protein PTMs (Figure 11D).
7.2.3 Validation of proteins identified with post-translational modifications
The identified modified peptides were further evaluated for accuracy. Being well stud-
ied and characterised PTMs, phosphorylation, acetylation and methylation were used for
cross-checking for whether peptides identified with the three modifications have been previ-
ously detected in other studies. The identified phosphopeptides in bone marrow proteome
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Figure 13: Validation of modified peptides with protein modification database. The identified phosphory-
lated, acetylated and methylated peptides were compared to curated protein phosphorylation, acetylation
and methylation databases. 95% -98% of the phosphorylated peptides detected in this study have been
previously identified in other PTM-targeted proteomics or biochemical analysis. Fractions of the acetylated
and methylated peptides identified in the database were 36% -62% and 63 -82%. The peptide matching
rates of all three modifications were approximately 2 times higher than the background peptide matching
rates, which are 42 -45% for phosphorylation, 17% -21% for acetylation and 7% -10% for methylation, as
indicated by the red dashed lines.
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were compared with all phosphopeptides annotated in PhosphoSitePlus database (version
of 2017.03.21) [Hornbeck et al., 2015]. Phosphorylation is by far the most extensively
studied protein PTM. Expectedly, 95% to 98% of the phosphopeptides have been previ-
ously identified in other PTM-targeted proteomics and biochemical studies (Figure 13).
In comparison, matching rate of unmodified peptides (background) to the phosphopep-
tides in PhosphoSitePlus database was only 42% to 45%. The peptide matching rates for
acetylated peptides and methylated peptides were 36 to 62% and 63 to 82% (Figure 13).
Though lower than phosphorylation, the peptide matching rates for the two modifications
were still at least two fold higher than peptide matching rates of the unmodified peptides
to the corresponding databases, which were 17% to 21% and 7% to10%, respectively. This
indicated that the modified peptides identified through mass tolerant database search is of
good quality.
7.2.4 Mass-tolerant database search identifies various forms of post-translational
modifications
Various forms of phosphorylation and methylation were identified, which were dehy-
drated phosphorylation, dehydrated and oxidised phosphorylation, dimethylation, hydrox-
ylated and deamidated methylation. The peptide matching rates for peptides with these
modification were summarized in Supplementary Figure 2. The rates were lower than the
classical phosphorylation and methylation but still more than 1.5 fold higher than back-
ground. Of note, the oxidized and dehydrated phosphorylation was inferred from the mass
shift peak with a mass shift value of -2.02 Da. This modification was initially identified as
2-amino-3-oxo-butanoic acid modification using annotation from Unimod database. But
most evidences showed that the modification that induces this mass shift is highly related
to phosphorylation. Correlation analysis with other modified peptides identified in the
study showed that peptides identified with 2-amino-3-oxo-butanoic acid modification have
the closest relation with oxidised peptides and dehydrated phosphopeptides (with Pear-
son correlation coe cient of 0.42 for both). Comparison with PhosphoSitePlus database
further showed that most of these spectrum have been previously identified in targeted
phosphorylation studies (Supplementary Figure 2). The combination of oxidation and de-
hydration of phosphorylated residue would induce a monoisotopic mass shift -2.01565 Da
on peptide, which is within 0.01Da tolerance of the mass shift value -2.02Da. In addition,
this modification was reported to occur on tyrosine and serine residues, which overlap with
residues for phosphorylation. Therefore, I reasoned that the modification that induces the
mass shift of -2.02Da is oxidized and dehydrated phosphorylation.
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Figure 14: Common modifications inside human bone marrow. A) in addition to 142,549 unmodified pep-
tides identified through standard database search, 30,137 modified peptides (16%) were identified through
standard database search with modifications included in dynamic search parameter. A significant amount
of modified peptides were oxidized and/or deamidated. B) deamidation (DA) and oxidation (Ox) were the
most frequently identified PTMs in human bone marrow, followed by various forms of phosphorylation,
methylation, acetylation and glycosylation. C) 6,528 phosphorylated peptides, 2,240 acetylated peptides
and 1, 877 methylated peptides were identified across six cell types in human bone marrow. 5% of those
modified peptides (n=1,534) were identified to have two and three di↵erent modified forms among the three
modifications, which may originate from regions where proteins have PTMs cross-talks. D) the number of
unmodified and modified proteins identified were at comparable levels across all six bone marrow-derived
cell types. 1,997 proteins in ERPs, 2,256 proteins in GRAs, 2,995 proteins in LYMs, 3,093 proteins in
MONs, 2,535 proteins in HPCs and 3,371 proteins in MSCs were modified, representing 55 to 60% of the
proteome of each cell type. E) the majority of the proteins were identified with low frequency of mod-
ification. Abbreviations: Ac, acetylation; DA, deamidation; Gl, glycosylation; Ph, phosphorylation; Me,
methylation; Ox, oxidation; P, phosphorylation; A, acetylation; M, methylation.
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Table 1: Identification rates of the most frequent protein PTMs in human bone marrow
Modification PSM % of All PSMs Peptide % of All Peptides Protein % of All Proteins
Oxidation1 383,015 8.00 18,215 11.91 3,891 52.08
Deamidation 397,550 8.30 16,848 11.02 4,020 53.81
Phosphorylation2 34,118 0.71 6,528 4.27 2,324 31.11
Methylation3 21,221 0.44 2,407 1.57 1,157 15.498
Acetylation 11,429 0.24 2,240 1.46 879 11.77
Reduction 6,519 0.14 1,597 1.04 983 13.16
Glycosylation4 2,710 0.06 880 0.58 500 6.69
Carboxylation 1,364 0.03 331 0.22 224 3.00
Quinone 1,078 0.02 312 0.20 218 2.92
7.2.5 Post-translational modifications are prevalent across bone marrow cell
types
From over 4.7 million high-confidence PSMs (with 1% protein FDR), 49,358 di↵er-
ent modified peptides forms from 4,701 proteins were identified(Table 1). Overall 16%
of the peptides in the bone marrow proteome were modified (Figure 14A). The major-
ity of the modified peptides identified were oxidized or deamidated peptides. 31% of the
modified peptides (n=9,415) from 3,269 proteins were modified by other common PTMs.
Among those common PTMs, phosphorylation, acetylation and methylation were the most
frequently detected modifications(Figure 14B). In addition to peptides modified by individ-
ual modifications, a fraction of the peptides (n=1,534) were modified with di↵erent types
of PTMs (Figure 14C).
The proportion of modified proteins were at comparable levels across all six cell types,
representing 55 to 60 % of the proteins identified in each cell type (Figure 14D). There were
1,997 modified proteins identified in ERPs, 2,256 proteins in GRAs, 2,995 proteins in LYMs,
3,093 proteins in MONs, 2,535 proteins in HPCs and 3,371 proteins in MSCs. Proteins
modified by PTMs other than oxidation and deamidation were proportionally larger in
MSC than in other cell types. In addition, proteins in bone marrow were observed to have
low modification levels. The majority of the bone marrow proteins were identified with
only one to two modifications (Figure 14E).
Phosphorylation, acetylation and methylation are the three most frequently detected
modifications apart from oxidation and deamidation. Therefore, I focused on these three
modifications in all the analysis presented in subsequent chapters.
1mono- and di-oxidation
2phosphorylation, dehydrated phosphorylation, dehydrated and oxidised phosphorylation
3mono- and di-methylation, hydroxylated and deamidated methylation
4fucose, hexose, acetylhexosamine and methylglyoxal
51
7.2.6 Modifications occur in specific sequence context
The same PTM occurs on di↵erent residues through various mechanisms and this could
be reflected through the amino acid context surrounding the modification site. Therefore
I further examined the amino acid preference flanking phosphorylation, acetylation and
methylation sites.
The amino acid preference surrounding phospho-serine (Sp) and phospho-threonine(Tp)
were highly similar (Figure 15A). Lysine (K) and arginine (R) were depleted in positions im-
mediate to the modified residue and enriched at distant locations. The negatively charged
aspartic acid (D) and proline (P) was highly enriched at adjacent positions. I observed an
enrichment at +2 position for proline around phospho-tyrosine (Yp) residues, compared to
the +1 preference in Sp and Tp. Most other amino acid distributions are similar between
Yp and Sp/Tp .
The patterns of amino acid frequency observed for methyl-lysine (Kme) and methyl-
arginine (Rme) were distinct from each other (Figure 15E). For peptides identified with
Kme, S and R were highly enriched at -1 and -2 positions whereas K was enriched at both
-2 and +2 positions. For peptides identified with Rme, methionine (M) was the preferred
residue before the modification site (-1 and -2 ) whereas negatively charged residues such
as K, R and histidine (H) appeared to be more frequent after the modification site (Figure
15F).
As each modified residues displayed a distinct pattern for the surrounding amino acids,
this suggested that the regulations of these modification may be sequence specific. Along
the same lines, I asked whether there is any specific enzyme generating the di↵erent PTMs
across di↵erent sequence context. This is especially applicable for phosphorylation because
the enzymes that target di↵erent phospho motifs are well studied.
Thus, I used pLogo to visualize the short linear pattern of amino acids surrounding
phosphorylated sites. Results showed specific amino acid patterns surrounding di↵erent
phosphorylation sites (Figure 16B). In agreement with the amino acid preference results
presented before, P was significantly enriched at the +1 position of both Sp and Tp, in
contrast to the preference at +2 for Yp. For all three phosphorylated amino acids, K was
unfavored before the modification site.
7.2.7 Phosphorylation, acetylation and methylation occur frequently on func-
tional domains in bone marrow
PTMs can occur on di↵erent regions of a protein to e↵ect and modulate di↵erent
biological functions. We can broadly understand these functions by 1) looking at which
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Figure 15: Amino acid preference neighbouring identified phosphorylation, methylation and acetylation
sites. The relative frequencies of 20 amino acid residues flanking sites of phosphorylation (A-C), acetyla-
tion (D) and methylation(E-F) were shown. Each modified residues displayed a distinct preferences for the
surrounding amino acids. Preference for proline close to modification sites, as well as depletion and enrich-
ment of lysine and arginine were observed in phosphorylated peptides. Charged residues such as lysine,
arginine and glutamic acid as well as hydrophilic residue threonine were preferred to be depleted before
acetyl-lysine, whereas lysine and arginine were frequently located away from acetyl-lysine site. Methionine
and glycine were highly enriched adjacent to a methyl-arginine but not methyl-lysine. Enrichment of hy-
drophilic residues such as histidine and tyrosine were observed in distant position from a methyl-arginine.
Lysine and arginine as well as hydrophilic residue serine were either enriched directly before or after a
methylation site.
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Figure 16: Functional analysis of phosphorylated, acetylated and methylated proteins. A) protein do-
mains enriched in phosphorylated, methylated and acetylated peptides (top five most frequent modified
domains, for structurally related domains, the most representative ones with the lower p values were chosen
for display) were involved in various functions, including enzymatic activity, ion- and RNA binding and
scal↵olding. B) motif enriched revealed proline enrichment in peptides with phosphor-serine and phosphor-
threonine. C) sequence enrichment of phosphorylated peptides uncovered known phospho-motif. The
identified phosphorylated peptides were previously identified as substrate of known kinases.
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functional domains the PTM occurs on and 2) which specific enzymes are utilised by the
cells to generate these modifications.
I first examined protein domains that are enriched for phosphorylated, acetylated and
methylated proteins. Among all phosphorylated, acetylated and methylated proteins, 412,
171 and 409 proteins domains were significantly enriched for each modification, respectively.
The most frequently modified domains were shown in Figure 16A. Notably, RNA-binding
motif (RRM) domain and thioredoxin domain/thioredoxin-like fold were enriched for all
three modifications. EF-hand domain pair were enriched in both phosphorylated and
acetylated proteins, indicating potential co-regulation between the two modifications.
For phosphorylated peptides, I further analyzed phospho-motif enrichment and used
these motif sequences to find their upstream kinases. Proteins were found to be targeted by
basophilic kinases and acidophilic kinases as basophilic kinase motif (PKA and PKC) and
acidophilic kinase motif (CKI and CKII) were identified in the peptide sequence analysis
(Figure 16C). Those kinases regulate a large repertoire of proteins with various activities
inside cells, suggesting that phosphorylation may actively regulate the function of the bone
marrow.
7.2.8 Hotspot of post-translational modifications in bone marrow showed as-
sociation between phosphorylation and other modifications
Protein PTMs hotspots, regions where multiple protein PTMs occur within the protein
are often the regulatory centre of a protein. The frequency of protein modification in
the hotspot also provides hints on the co-regulation of protein PTMs on protein function.
The identified phosphorylated, methylated and acetylated peptides from the bone marrow
proteome enabled me to examine the co-occurrence of these modifications inside human
bone marrow.
In total, 305 protein PTM hotspots from 166 proteins were observed in the bone mar-
row proteome(Figure 17A). The majority of the proteins with PTM hotspot contain 1 to 2
hotspots. Only 3% of the proteins with PTM hotspot have over 5 regions that were heavily
modified. The 305 protein PTM hotspots can be further divided into subgroups according
to the composition and frequency of the modifications detected within the hotspot (Figure
17B). 67 hotspots were identified to have phosphorylation, acetylation and methylation,
representing 22% of all identified hotspots. The combination of phosphorylation and acety-
lation were the most predominant co-occurring PTMs inside bone marrow. Together they
regulated 39% of the identified hotspots (n=119).
As an example of protein with PTM hotspots, heterogeneous nuclear ribonucleoproteins
A2/B1 (hnRNP A2B1) was shown in Figure 17C. Three PTM hotspots were identified
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Figure 17: Co-occurrence of protein post-translational modifications inside bone marrow. A) 305 protein
PTM hotspots were discovered from 166 proteins in human bone marrow. The majority of the proteins
harboured singular PTM hotspot. 9 proteins (3% of the proteins identified with PTM hotspot) were found
to have over 5 regions that were heavily modified. B) according to the modifications and the proportion of
each modification in each hotspot, the 305 PTM hotspots were clustered and further divided into subgroups.
67 hotspots were regulated by phosphorylation, acetylation and methylation, 21 by phosphorylation and
methylation, 119 by phosphorylation and acetylation. Co-regulations were observed in 19 hotspots. C)
in total three PTM hotspots were identified in heterogeneous nuclear ribonucleoproteins A2/B1 (hnRNP
A2B1). The three hotspots were located in close proximity, but the modifications harboured within each
hotspot were distinctively di↵erent. The first two hotspots were predominantly regulated by phosphoryla-
tion and acetylation, whereas the third hotspot was regulated mostly through methylation. Abbreviations:
P, phosphorylation; A, acetylation; M, methylation.
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Figure 18: Cross-talks between phosphorylation and other modifications. Distances of acetylation and
methylation to the nearest phosphorylation site (up to 500 amino acid distance) on the same protein were
calculated. From the proportion of phosphorylation peptides containing a nearest secondary PTM sites it
can be seen that majority of the co-occurring phosphorylation and other PTMs were concentrated within
a distance 100 amino acids from the phosphorylation site. In addition, in the region 10 to 20 amino acids
away from a phosphorylation site, acetylation was significantly more frequent in comparison to methylation.
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in hnRNP A2B1. The three modification hotspots were located in close proximity, but
showed distinct di↵erences of the composition of modifications. The first two PTM hotspots
were identified to contain mostly phosphorylation and acetylation sites, whereas the third
hotspot appeared to be predominantly regulated by methylation.
As phosphorylation often appeared to occur together with other modifications, I fur-
ther analysed the frequencies of phosphorylation in the vicinity of a second PTM. For a
phosphorylated protein, I asked what proportion of phosphorylated residues are within a
certain amino acid distance, given a methylation or acetylation site. Results showed that
the co-occurrence of phosphorylation with other modifications were mostly concentrated
within 100 amino acids away from a phosphorylation site (Figure 18). In addition, a high
correlation of acetylation and phosphorylation in short distance was observed. 30% of all
identified co-occurring acetylation and phosphorylation were located 10 to 20 amino acids
apart from each other. Compare to other modifications, acetylation also co-occurred more
frequently with phosphorylation within 20 amino acids from phosphorylation site.
7.3 Discussion
7.3.1 Bone marrow proteome is extensively modified
The data from the six cell types provided an overview of the proteome of human bone
marrow microenvironment. As one of the major human tissue, the bone marrow pro-
teome has been extensively studied using a combined approach of next generation RNA-
sequencing and in situ a nity-based proteomics by human proteome atlas [Andersson et al.,
2014,Uhle´n et al., 2015]. This study is by far the first in-depth quantitative proteomics
analysis on the human bone marrow niche. The spectrum identification rates of this study
are comparable to the identification success rate of a typically LC/MS proteomic-type
analysis, which is between 5 to 15% [Keller et al., 2002]. The captured proteome well-
represented the content of the human bone marrow as 65% genes transcribed in the bone
marrow were identified. Proteins that have been previously identified at mRNA level but
not in this proteomics study may be explained by low transcription level or low translation
e ciency.
The results further illustrated the scale and diversity of the modifications inside human
bone marrow. With the combined strategy of using both standard and mass-tolerant
database searches, I showed that the human bone marrow is modified by a variety of
protein PTMs, including phosphorylation, methylation and acetylation. In addition, it is
also observed that some modifications are specifically enriched in a few cell populations. For
example, peptides with reduction were predominantly identified in MSCs whereas quinone
modification were mostly found in ERPs. This suggests that cell-type specific modifications
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exists inside bone marrow, which may fine-tune the functions of a subpopulation of the
bone marrow cells.
7.3.2 Frequently modified proteins in bone marrow regulate diverse spectrum
of functions
In order to further understand the functions of the common PTMs inside human bone
marrow, domains enriched for phosphorylated, acetylated and methylated peptides were
examined. Domains with the highest propensity to be modified across all domain detected
were thioredoxin domain, RNA recognition motif (RRM) domain and EF-hand domain.
The majority of proteins containing thioredoxin domain are evolutionary related to
thioredoxin [Hanschmann et al., 2013]. They act as major cellular protein disulfide reduc-
tases and are key regulators of redox-mediated signaling. Phosphorylation of thioredoxin-1
(Trx) T100 is reported to be mediated through PKC-dependent pathway [Chen et al., 2010].
The phosphorylation of Trx contributes to its nuclear location, and up-regulates the activ-
ity of NF-kappaB. In addition, phosphorylated Trx serve as an inhibitor of ASK1, a protein
kinase responsive to stress stimuli and involved in cellular processes such as di↵erentiation,
apoptosis and autophagy [Yoon et al., 2009]. Other modifications on thioredoxin domain
have been observed in other proteins mostly in proteomics studies, such as acetylation and
nitrosylation on Trx and Trxr 1 [Rush et al., 2005,Weichsel et al., 2007,Choudhary et al.,
2009]. However, the regulatory function of each modification remain to be characterized.
Similarly, protein with RRM domain have a variety of RNA-associated functions, from
regulating alternative splicing to maintaining RNA stability and translation. Phosphoryla-
tion, methylation and SUMO modification of RRM have been described in previous studies
and are known to regulate the conformation and stability of RRM proteins [Schullery et al.,
1999,Glisovic et al., 2008].
Proteins with EF-hand domain are regulated through binding of calcium ions [Ermak
and Davies, 2002,Mazumder et al., 2014]. Calmodulin and calcineurin are the best repre-
sented proteins among the EF-hand superfamily, which are known to indirectly regulate
transcription factors in response to Ca2+ concentration. Modifications such as phospho-
rylation and methylation of EF-hand domain have been identified in mass spectrometry
based studies in di↵erent human tissues, including liver cells and T lymphocytes [Raftery
and Geczy, 1998,Carrascal et al., 2008,Olsen et al., 2010,Bian et al., 2014].
Taken together, domains enriched with phosphorylation, acetylation and methylation
are involved in cellular processes covering from regulating gene transcription to cell dif-
ferentiation and apoptosis. The extensive coverage of functions implies that PTMs may
play an important part for sustaining the functions of bone marrow. In addition, the high
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frequency of PTMs and potential co-regulation between PTMs on these domains further
suggested that thioredoxin domain, RRM domain and EF-hand domain may serve as the
centre hub of PTMs in human bone marrow.
7.3.3 Phosphorylation regulates bone marrow proteins through cross-talk with
other PTMs
From an evolutionary point of view, combinations of di↵erent PTMs is an e cient
strategy for cell to cope with stimuli as they provide immediate response, faster than
controlling translation or transcription. Regions of amino acid sequences with high density
of PTMs are often known as the PTM hotspot. PTM hotspot functions as regulatory
centres and have been described in many proteins, such as histones and p53 [Bannister
and Kouzarides, 2011,Brooks and Gu, 2003]. Therefore, I investigated the co-regulation of
di↵erent PTMs by analyzing the PTM hotspots inside the human bone marrow.
The wide occurrence of phosphorylation in PTM hotspots highlights phosphorylation
as a key PTM for bone marrow. The PTM hotspots identified in the bone marrow can be
divided into two subgroups, the ones regulated by single PTM and the ones by multiple
PTMs. Among the three common PTMs analysed in this study, phosphorylation dominated
most of the single PTM hotspots and also participated in the majority of the hotspots
of combined PTMs. Phosphorylation is known to often co-occur or compete with other
PTMs, including acetylation, methylation, glycosylation and ubiquitylation [van Noort
et al., 2012,Swaney et al., 2013,Zeidan and Hart, 2010,Este`ve et al., 2011,Fang et al., 2014,
Biggar and Li, 2015]. In addition, phosphorylated proteins were found to reside in central
network positions and have pairwise interactions with other proteins PTMs [Duan and
Walther, 2015]. The observed high frequency of co-occurring modifications in the vicinity
of phosphorylation suggested that the function of these hotspot regions can be modulated
by PTM crosstalk. The observed high frequency of phosphorylation co-occurring with
other PTMs is in agreement with the previous studies, and further underscore the central
importance of phosphorylation in regulating human bone marrow proteome.
7.3.4 Interplay between phosphorylation and acetylation may be functionally
important for bone marrow proteins
The strength of a PTM in the vicinity of a secondary PTM ( based on the number
of modified peptides detected) provides information on whether the two modifications
could be physically interacting. Results on the distance of a phosphorylation site to its
nearest modification showed that the majority of the modifications are distributed evenly
across the protein sequence, whereas acetylation was more frequently located surrounding
a phosphorylation site within 10 to 20 amino acid distance.
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At the proteome level, acetylation has been reported to co-occur frequently with phos-
phorylation in genome-reduced bacterium M.pneumoniae [van Noort et al., 2012]. The
cross-talk between phosphorylation and lysine acetylation often co-occurs within the same
protein at the interaction interfaces as well as on multifunctional proteins. In addition, the
conservation of phosphorylation near acetylation sites was found to be relatively high, fur-
ther hinting functional co-regulation [Beltrao et al., 2012]. The pattern of co-occurrence for
phosphorylation and acetylation on the same protein was also observed on human protein
data sets [Duan and Walther, 2015]. Hence, the observed co-occurring phosphorylation
and acetylation could be of functional importance to the human bone marrow.
At the protein level, co-regulation of phosphorylation and acetylation in short-distance
has also been observed on individual proteins. For example, phosphorylation and acetyla-
tion co-regulate the intracellular location of FOXO. Acetylation of FOXO1 diminishes its
binding to DNA, increasing its phosphorylation by AKT, which leads to association with
14-3-3 proteins and cytoplasmic retention [Matsuzaki et al., 2005]. In addition, co-occurring
phosphorylation and acetylation in close proximity is also known to induce conformational
changes necessary for the recognition of ’reader’ proteins. Both phosphorylated and acety-
lated of CREB are required for its interaction with CBP and the formation of ternary
complex with CBP KIX and BRD domains [Paz et al., 2014]. On the other hand, a neg-
ative regulation between acetylation and phosphorylation has also been reported in the
case of p53 [Ou et al., 2005]. Therefore we propose that the proteins identified with phos-
phorylation and acetylation in close proximity may serve as good candidates for further
co-regulation analysis.
7.3.5 Use mass-tolerant database search method to extend understanding on
protein modifications
The combined method of standard and mass-tolerant database search addressed 17.86%
of the spectra that were unassigned when only the standard database search was applied.
A previous study estimated over one third of the unassigned spectra have substoichmetric
modifications [Chick et al., 2015]. By this measure, I have recovered half of the potentially
modified peptides. I validated most of the phosphorylated, methylated and acetylated
peptides through in-silico methods. To provide additional confirmation for the identity of
the modified peptides, one could compare the spectra information to those in the mass
spectrometry peptide database such as PeptideAtlas.
The remaining unassigned spectra could be attributed to the following factors: combi-
nations of modifications, peptides modified by lowly abundant PTMs that do not generate
strong signals to be detected as peaks, and amino acid variants due to genetic polymor-
phisms. These modifications were not covered in the scope of this study, but can be
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addressed with similar approaches. Of note, though computationally challenging for large-
scale datasets, increasing the search windows in mass-tolerant database search and in-
cluding lowly abundant PTMs in the second standard database search could potentially
recover many of those modified peptides and provide more insights on the functions of
those modifications.
7.4 Conclusion and perspective
The human bone marrow proteome was measured by quantitative high-resolution tan-
dem mass spectrometry in this study. With the combination of standard and mass-tolerant
database search method, protein PTMs within the human bone marrow were systemati-
cally analyzed. The human bone marrow proteome was found to be extensively modified.
Common modifications such as phosphorylation, acetylation and methylation were found
to be present in up to one third of the bone marrow proteins, and may modulate impor-
tant cellular processes within the bone marrow. The specific patterns from phosphorylated,
acetylated and methylated peptides revealed the sequence preferences for each of the modi-
fication. Analysis on the cross-talks between di↵erent PTMs further suggested phosphory-
lation plays an important role in regulating activities of bone marrow proteins, on its own
and also in orchestration with other modifications. In addition, the short distance between
phosphorylation and acetylation sites further suggested the presence of co-regulation of the
two modifications is a common feature and may be functionally important to the human
bone marrow.
Arguably the study gives a partial view of the entire modification landscape of the bone
marrow proteome. Some modifications such as phosphorylation are unstable in-vitro and
and may be easily lost during experiment. As the study aimed at unbiasedly profiling
the protein modification landscape inside the human bone marrow, further PTM-oriented
analysis can provide a more comprehensive understanding of the PTMs inside human bone
marrow, either for a specific modification or for subpopulation of bone marrow derived
cells. PTMs that induce molecular weight shift over 500Da, as well as combinations of dif-
ferent PTMs, which were omitted in the study could be explored via in-silico approaches.
In addition, the identified PTMs as well as the modified proteins require further valida-
tion to confirm their presence of modification in-vitro and in-vivo. Additional analysis on
spacial proximity in three-dimensional structure will provide insights on the functional rela-
tionships between phosphorylation and other modification inside the human bone marrow.
Furthermore, for the co-regulation between phosphorylation and acetylation, functional
analysis would help to understand whether the mode of co-operation is competitive or
cooperative regulation.
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8 Protein Phosphorylation, Acetylation and Methylation
Display Di↵erences Across Bone Marrow Cells
8.1 Summary
In this study, the proteome of human bone marrow was analysed using tandem mass
spectrometry. Enriched protein PTMs were first deduced through mass-tolerant searches
and re-identified using standard database searches. Following the establishment of the
mass-tolerant database search method for the project and profiling the dynamics of pro-
tein PTMs of the bone marrow proteome, the di↵erences between the protein modification
status among haematopoietic progenitors (HPCs), lymphoid progenitors (LYMs), mono-
cyte progenitors (MONs), erythroid progenitors (ERPs), granulocyte progenitors (GRAs)
and mesenchymal stromal cells (MSCs) were examined. The three most frequently detected
modifications (apart from oxidation and deamidation), phosphorylation, acetylation and
methylation were further analyzed for their profiles across cell types. In this chapter, pro-
tein modifications that display cell-type dependency across the six cell types are presented.
8.2 Result
8.2.1 Profiles of phosphorylation, acetylation and methylation in bone marrow
show cell-type dependencies
Bone marrow proteins were frequently modified. Phosphorylation, acetylation and
methylation were the most frequently detected modifications and are the focus of my
analysis in the following chapters. In total across six di↵erent bone marrow cell types,
there were 2,324, 950 and 879 proteins identified to be phosphorylated, methylated and
acetylated, respectively.
To understand the distribution of the modified proteins in di↵erent bone marrow cells,
we analyzed the similarities between the occurrences of phosphorylation, methylation and
acetylation on modified proteins. For the modified proteins that were detected across all six
cell types, I used the Jaccard index to estimate how similar are the modifications (whether
it is phosphorylated, methylated or acetylated across any of the six cell types) between
those proteins. This pairwise distance measure was calculated, subjected to hierarchal
clustering, and the results are plotted together with the number of modified peptides
(Figure 19A). Phosphorylation was more wide-spread than acetylation and methylation
and also co-occurred frequently with acetylation and methylation. In addition, there were
201 proteins detected to be solely phosphorylated in MSCs. These proteins were expressed
in all six cell types, however no phosphorylated nor acetylated nor methylated forms were
identified in the other five cell types. Hierarchical clustering of proteins identified to be
phosphorylated, acetylated or methylated also revealed that profiles of modification in
haematopoietic lineage cells were more closely related. In particular, MONs and LYMs
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Figure 19: Distributions of phosphorylated, methylated and acetylated proteins across bone marrow cells.
A) phosphorylated, methylated and acetylated proteins across 6 types of bone marrow cells were clustered
based on similarity of modification profiles. Frequently modified proteins were depicted in light yellow and
proteins have no modification(s) were depicted in dark blue. B) phosphorylated, methylated and acetylated
proteins across 6 cell types were classified according to the cell types. C) In total 884 phosphorylated
proteins, 345 acetylated proteins and 175 methylated proteins were tested for di↵erential modification
across cell types. 238, 153 and 56 proteins showed to significantly di↵erent levels of phosphorylation,
acetylation and methylation among the six bone marrow derived cell types (FDR < 0.05). The cell type
with the highest propensity for di↵erentially modified proteins varied according to modification, with ERP
being highest for phosphorylation, HPC for acetylation, MSC and GRA for methylation.
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showed closest relationship for all three modifications. On the contrary, the modification
profile of MSCs was most distant from the profiles of the five haematopoietic cell types.
Overall the patterns of phosphorylation, methylation and acetylation were distinct across
six cell types.
Di↵erent PTMs often modify on the same protein to co-regulate its function, there-
fore we further analyzed modified proteins for PTM co-occurrence. In total 1,048 proteins
were identified with combinations of phosphorylation, acetylation and methylation(Figure
19B). The proportion of proteins identified with all three modification co-occurring and in
all six cell types was 28% (n=133). This proportion was much higher than the percentage
of proteins identified with other combinations of co-occurring modifications in all six cell
types, which were in between 6 to 9%. The 133 proteins with co-occurring phosphoryla-
tion, acetylation and methylation were enriched for signalling pathways including platelet
degranulation and activation, glycolysis, RHO GTPase activity and mRNA splicing (Sup-
plementary Figure 4).
8.2.2 Phosphorylated, methylated and acetylated proteins were di↵erentially
regulated across bone marrow cells
Phosphorylated, acetylated and methylated proteins were further analyzed for di↵eren-
tial modification rates across cell types. For each modified protein, the number of PSM
detected from its modified peptides was on average 1 to 2, whereas that for the unmodified
peptide is between 10 to 20. At this low number, the estimate of modification frequency
(modified peptide counts divided by unmodified peptide counts) tends to be imprecise,
making it di cult to identify significant variation that are above the noise. Therefore, to
overcome this problem I used all modified peptides identified for each protein to collectively
estimate the modification frequency at the protein level.
To compare the modification frequency across cell types for a given protein, the pro-
portion of its modified peptides (with respect to the unmodified peptides) was compared
across all 6 cell types using an extension of Fisher's exact test. Only proteins with at
least 10 unmodified peptides and 3 modified peptides for each modification were analyzed.
With an FDR < 0.05, in total 27 to 44% of the proteins showed significantly di↵erent lev-
els of phosphorylation, acetylation and methylation across the six bone marrow cell types
(Figure 19C). These di↵erential regulations were often driven by very strong modification
signals in one (or two) cell types(s) compared to the others. For phosphorylation, ERPs
had the highest modification propensity, followed by MONs and MSCs. For methylation,
GRAs and ERPs had the most di↵erentially regulated proteins, whereas the majority of
the di↵erentially acetylated proteins (61%) can be attributed to highly acetylated proteins
in HPCs.
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Figure 20: Mapping di↵erentially phosphorylated and acetylated proteins with signalling pathway revealed
cell-type specific regulations. Proteins di↵erentially phosphorylated (n=238) and methylated (n=153) were
mapped to Reactome database. Pathways that were significantly enriched for each modification were shown
(FDR < 0.05). The size of the dots indicated the number of proteins that fall into each pathway, and colour
of the dots represented the statistical significance of the enrichment. Pathways at the same level but under
the same parental pathways were collapsed and only the ones with lowest p values were shown here.
Figure 21: Over-represented biological processes, molecular functions and cellular components of di↵eren-
tially methylated proteins. 56 di↵erentially methylated proteins were tested for over-representation in Gene
Ontology association for biological process(BP), molecular function(MF) and cellular components (CC)
(FDR < 0.05). Similar GO terms at the same level but under the same term were collapsed and only the
ones with highest count were shown here.
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In order to reveal the functions of those di↵erentially modified proteins, I tested for
significantly enriched pathways for the di↵erentially phosphorylated and acetylated proteins
(Figure 20). The enriched pathways indicated that the di↵erential PTM is not restricted
to a few proteins, but rather the varying regulation of phosphorylation and acetylation is
spread over di↵erent junctures of pathways. It is reasonable to consider that these pathways
may be relevant for the function of individual cell types.
Proteins di↵erentially methylated were not enriched in any particular pathways. Gene
ontology analysis showed that these proteins were involved in ’de novo protein folding’ and
’de novo post-translational protein folding’ (Figure 21). The majority of the di↵erentially
methylated proteins were enriched for structural components of cells, mostly located on
the cell membrane, extracellular components and cell junction.
8.2.3 Site-specific regulation on phosphorylated, methylated and acetylated
bone marrow proteins
For the same modification, proteins can also display significant di↵erences in terms of the
modification sites while the overall modification frequencies remain unchanged across cell
types. Therefore, I investigated the heterogeneity of modification sites for phosphorylated,
acetylated and methylated proteins across six cell types. To overcome the problem with low
number of PSM per modified peptide as mentioned, a Chi-square based test was applied
to detect significant variations in modification frequency for each site in a given protein.
In total 87 proteins (FDR < 0.05) showed significant variability for modification sites, of
these 70 were identified with phosphorylation di↵erences, 5 for methylation and 36 for
acetylation (Figure 22A).
In addition to di↵erences on single PTM, 25 proteins showed positional di↵erences for
more than one modification(Figure 22A). Figure 22B showed EEF1A1 as an example to
illustrate the bias at each modification site. T261p was the most predominant phosphory-
lation site, however the secondary phosphorylation site of EEF1A1 varied across cell types.
Acetylation of EEF1A1 displayed heterogeneous patterns as the dominant modification
sites varied across cell types. The most frequently acetylated sites were C411 in MSCs,
K255 in LYM, K439 in HPC and K386 in ERP. For MON and GRA the acetylation sites
were identified to be evenly distributed across the entire protein.
8.2.4 Heteronuclear binding proteins are di↵erentially modified RNA-binding
proteins in human bone marrow
To understand functions of the di↵erentially modified proteins, I further analyzed the
composition of proteins in the common pathways enriched for di↵erentially phosphorylation
and acetylation (Figure 20). Interestingly, proteins enriched in the mRNA splicing pathway
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Figure 22: Preferences of modification site varied across cell types in human bone marrow. A) in total 70
proteins in the human bone marrow showed significant variations for phosphorylation sites, 5 proteins for
methylation sites and 36 proteins for acetylation sites. B) dot plots depicted ratio of spectral counts of
the phosphorylated and acetylated peptides to the unmodified peptides observed across six cell types for
sites along the length of EEF1A1. T261p was found as the dominant phosphorylation site in all cell types
whereas secondary phosphorylation sites showed great variability across cell types. Acetylation of EEF1A1
displayed heterogeneous patterns as the dominant modification sites varied across cell types. The most
frequently acetylated sites were C411 in MSCs, K255 in LYM, K439 in HPC and K386 in ERP. For MON
and GRA the modifications were identified to be evenly distributed across the entire protein.
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Figure 23: Heteronuclear binding proteins were preferentially acetylated in haematopoietic progenitor cells.
A) over half of the hnRNP proteins identified in the human bone marrow proteome were di↵erentially
modified. Acetylation regulate the 8 of the 10 di↵erentially modified hnRNP proteins. B) percentage of
modified peptide counts to the unmodified peptides counts for each di↵erentially modified hnRNP in six
cell types were shown to illustrate the modification preference across six cell types. Acetylation regulated
and co-regulated the majority of the di↵erentially modified hnRNP proteins. Proteins that did not have
the corresponding modified form detected were shown in white.
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Figure 24: Di↵erentially regulated phosphorylation, acetylation and methylation sites were concentrated
in RNA-recognition motif domains on heteronuclear binding proteins. The di↵erentially phosphorylated,
methylated and acetylated hnRNP proteins and the modification sites found for each hnRNP were shown.
Together with other two modification, acetylation co-regulated the majority of the di↵erentially modified
proteins. For proteins with RNA-recognition motif (RRM) domain, majority of the acetylation sites were
located within the domain. For hnRNP U, which does not contain RRM domain, the modifications were
mostly on its P-loop domain. In addition, competitions between acetylation and phosphorylation, acety-
lation and methylation were also observed within the RRM domains of hnRNP A2B1, hnRNP A1 and
hnRNP M.
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Figure 25: Modification sites on di↵erentially regulated heteronuclear binding proteins are are in selected
regions on RRM. A) sequence alignment of di↵erentially modified hnRNP proteins with RRM domains
revealed that the modification sites were mostly located in regions in between  -sheets, which form RNA-
binding surface on RRM domain. The identified modification sites shared similar chemical properties across
subset of hnRNP proteins. Modifications identified within the selected regions were highlighted in colour
according to the modification, which were: Y128p, K130ac, T138p, S158p and T169p for hnRNP A1;
T123,Y135p, K137ac, T145p, K168ac, Y174p and T176p for hnRNP A2B1; K67ac and K76ac for hnRNP
H3; K239p and K239ac for hnRNP M; K89ac for hnRNP C; T25p, S38p and Y67p for hnRNP CL2.
B) X-ray crystal structure of hnRNP A2B1(residue 15-193) in complex with 10-mer RNA (PDB: 5HO4).
Acetylation sites K137 and K168 were highlighted in green. Phosphorylation sites T123 , Y135, T145, Y174
and T176 were highlighted in cyan. C) solution structure of hnRNP C (residue 2-106) in complex with
5-mer RNA (PDB: 2mxy). The identified acetylation site K89 was highlighted in green.
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were all members from the heteronuclear binding protein (hnRNP) family. This further
prompted me to examine this group of proteins in detail.
In total, there are 24 human hnRNP proteins annotated in UniprotKB database, 19
of which were detected in the human bone marrow (Figure 23A). Among the 19 hnRNP
proteins detected, 10 of them were found to be di↵erentially phosphorylated or acetylated.
The di↵erentially acetylated hnRNP proteins constituted the majority of the di↵erentially
modified ones, 42% of all hnRNP proteins detected. The 5 hnRNP proteins not detected
in this proteomics dataset could be explained by their low mRNA level in the human bone
marrow, as shown in the study by Uhlen et al. [Uhle´n et al., 2015].
The 10 di↵erentially modified hnRNP proteins displayed distinct patterns across cell
types (Figure 23B). Acetylation of hnRNP proteins were predominantly observed in HPCs.
Furthermore, hnRNP A2B1 and hnRNP A1 also contained modification sites that showed
positional di↵erences across di↵erent cell types (Supplementary Figure 8).
I verified the modification sites on hnRNP proteins through cross-checking with mod-
ification database PhosphoSitePlus. The majority of the modified residues detected on
hnRNP proteins have been identified in previous studies. Phosphorylation sites, such as
Y135, T145, Y174 and T176 on hnRNP A2B1, Y128, T138, S158 and T169 on hnRNP A1,
have been identified in other proteomics studies [Tsai et al., 2015,Pinto et al., 2015,Levin
et al., 2016]. Acetylation site such as K168 on hnRNP A2B1 has also been found in previous
studies [Wu et al., 2015]. Interestingly, the majority of the detected acetylation sites, such
as K67 and K76 on hnRNP H3, K137 on hnRNP A2B1, K89 on hnRNP C, were identified
ubiquitination sites [Kim et al., 2011,Mertins et al., 2013]. The detected methylation site
K692 on hnRNP M has also been identified as a ubiquitination site [Kim et al., 2011].
To understand the e↵ect of modifications, I further examined the locations of those
modification on hnRNP proteins. The modification sites identified for all di↵erentially
modified hnRNPs were predominantly located within the RRM domains of the hnRNP
proteins (Figure 24). Phosphorylation of hnRNP U, which atypically does not contain a
RRM domain, was on its SAP domain, p-loop domain as well as on regions in between the
three domains. For the hnRNP proteins di↵erentially modified by combination of PTMs,
the detected acetylation sites were often located in close proximity with phosphorylation
or methylation within the RRM domains.
Why is there a preference for modification on RRM domains? The RRM domains of
hnRNP proteins are highly conserved across species (Supplementary Figure 5 - 7). Sequence
alignment of the di↵erentially modified hnRNP proteins with RRM domain showed that
the identified modification sites were mostly clustered in selected regions within the RRM
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Table 2: Resolved structures of the di↵erentially modified heteronuclear binding proteins
Name PDB Type Residue Domain
hnRNP R 2dk2 NMR 333-416 3rd RRM
hnRNP L 3to8 X-ray di↵raction 1.82A˚ 380-589 C-terminal RRM
hnRNP H1 2lxu NMR 7-111 N-terminal RRM
hnRNP C 2mxy, 2mz1 NMR 2-106 N-terminal RRM with 5-mer RNA
hnRNP U 1zrj NMR 1-37 SAP
hnRNP A2B1 5ho4 X-ray di↵raction 1.85A˚ 15-193 N-terminal RRM with 10-mer RNA
hnRNP A1 1l3k X-ray di↵raction 1.1A˚ 1-196 two N-terminal RRM
hnRNP M 2do0, 2dgv NMR 196-296, 652-730 2nd and 3rd RRM
domain. Aligned regions where modifications were clustered revealed that modification
sites appeared to share similar properties across subsets of hnRNP proteins in human
(Figure 25A). For hnRNP A2B1 and hnRNP A1, multiple residues aligned on the same
positions were identified to have the same modification, such as acetylation site T110ac on
hnRNP A2B1 and T102ac on hnRNP A1, as well as co-occurring pattern Y135p/ K137ac
on hnRNP A2B1 and Y128p/K130ac on hnRNP A1. Taken together, these suggest that
RRM domains have evolutionary conserved features and PTMs on this regions could be
an e↵ective mechanism for regulating the function of hnRNP proteins.
To understand the potential regulatory mechanisms of these modifications on RRM, the
identified modification sites were further mapped to the crystal structures of the hnRNP
proteins. Among the 10 di↵erentially regulated hnRNP proteins, 8 proteins have their
partial structures resolved (Table 2). Among those, hnRNP A2B1 and hnRNP C have
structures in complex with RNA and are illustrated as examples (Figure 25 C-D). hnRNP
A2B1 (residue 15-193, first two RRM domain) was crystallised in complex with a 10-mer
RNA (PDB: 5HO4), whereas the structure of hnRNP C (residue 2-106) was resolved in
complex with a 5-mer RNA by NMR spectroscopy (PDB: 2mxy). The identified modifi-
cation residues on hnRNP A2B1 and hnRNP C (highlighted in colours) were all located
in regions away from the RNA binding groove, mostly in between the  -sheets as well as
sporadically on the ↵-helices. Crystal structures of other hnRNP proteins were also in
agreement with the observation that the majority of the identified modification sites were
away from the RNA binding surfaces (Supplementary Figure 9). These modifications sites
were unlikely to directly interfere but could play an auxiliary role in RNA binding.
8.2.5 Glucose metabolism is di↵erentially regulated through phosphorylation
and acetylation across di↵erent cell types in bone marrow
Glycolysis pathway was enriched for both di↵erentially phosphorylated and acety-
lated proteins, highlighting its importance as a central energy metabolism pathway across
di↵erent bone marrow cells (Figure 20). I further examined all proteins associated with gly-
colytic pathways for their modification frequencies in order to have a comprehensive view
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Figure 26: Di↵erentially modified proteins in glycolysis pathways displayed preferences for acetylation and
phosphorylation across cell types. ↵-enolase (ENO1),  -enolase (ENO3), phosphoglycerate kinase 1(PGK1),
fructose-bisphosphate aldolase A (ALDOA), pyruvate kinase (PKM) and glyceraldehyde-3-phosphate dehy-
drogenase (GAPDH) showed significant variability for frequencies of both phosphorylation and acetylation
in bone marrow cells. For a given protein, the modification frequency was shown by the ratio of modified
peptide counts versus its unmodified peptide counts, with acetylation coloured in green and phosphorylation
in blue. HPCs displayed a preference towards acetylation for all proteins. The frequencies of acetylation of
those proteins in HPCs were also the highest among all six cell types. For the other 5 cell types, modification
of the 6 di↵erentially modified proteins showed preferences towards phosphorylation.
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Figure 27: Phosphorylation and acetylation on glycolytic proteins displayed positional di↵erences across cell
types. Three proteins, namely PGK1, PKM, GAPDH, displayed cell-type dependent preferences for both
phosphorylation and acetylation sites. For the three proteins, MSCs displayed unique modification pattern
di↵erent from ones from cells from haematopoietic lineage. Dominant modification sites, such as Y390p
and C358ac in PKM, S125p, T184p, S125ac, T176ac in GAPDH were only detected in high frequencies in
MSCs. For modification sites identified in haematopoietic lineage cells, the phosphorylation and acetylation
sites also showed high variability across cell types.
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of the entire pathway. The results showed that the majority of the modified proteins in the
glycolytic pathway have similar modification frequencies across cell types (Supplementary
Figure 11). The di↵erentially phosphorylated and acetylated proteins were involved only
in the fructose metabolism pathway.
In total 7 proteins annotated in the glycolytic pathways showed variability for their
phosphorylation levels, including ↵-enolase (ENO1),  -enolase (ENO3), phosphoglycer-
ate kinase 1(PGK1), fructose-bisphosphate aldolase A (ALDOA), pyruvate kinase (PKM),
glyceraldehyde-3-phosphate dehydrogenase (GAPDH) and phosphoglucomutase-1 (PGM1).
Except PGM1, all di↵erentially phosphorylated glycolytic proteins were also di↵erentially
acetylated.
In order to find the potential PTM co-regulation in the glycolytic pathway, I further
compared the frequencies of phosphorylation and acetylation for the 6 proteins both di↵er-
entially phosphorylated and acetylated (Figure 26). HPCs displayed preferred acetylation
for all 6 proteins. The frequencies of acetylation of those proteins in HPCs were also the
highest among all six cell types, whereas the frequency of phosphorylation for those pro-
teins in HPCs were lower. For the other 5 cell types, the 6 di↵erentially modified proteins
showed tendencies to be phosphorylated as opposed to be acetylated.
The majority of the phosphorylation and acetylation sites on those proteins have been
detected in previous studies, but none of them directly a↵ect the enzymatic functions of
those proteins. Most of the frequently detected acetyl-lysines and phosphoryation sites on
PGK1, PKM2 and GAPDH have all been detected in previous proteomics studies [Mertins
et al., 2013, Kim et al., 2011, Kettenbach et al., 2011, Tsai et al., 2015]. A few of the
modified residues have been validated in biochemical studies and these include S203p on
PGK1, K305ac, S202p and Y390p on PKM2, K117ac and T246p on GAPDH [Lv et al.,
2011,Ventura et al., 2010,Li et al., 2016,Park et al., 2016b,Yogalingam et al., 2013,Qvit
et al., 2016,Hitosugi et al., 2009].
To further understand the regulation on glycolytic pathway through PTMs, I ana-
lyzed the modification sites identified for each di↵erentially phosphorylated and acetylated
proteins. Among the three proteins that have both phosphorylation and acetylation sites
di↵erentially regulated, MSCs displayed unique modification pattern di↵erent from ones
from the haematopoietic lineage cells (Figure 27). Dominant modification sites, such as
Y390p in PKM, S125p and T184p in GAPDH were only detected and identified with high
frequencies in MSCs. For modification sites identified from cells of haematopoietic origin,
the phosphorylation and acetylation sites also showed cell-type preferences. For example,
S202 phosphorylation on PKM2 was consistently observed in cells from haematopoietic
76
lineage but proportionally higher in the HPC population. Similarly, K117 acetylation on
GAPDH was also observed in all cell types but the percentage is highest in HPCs.
In conclusion, proteins in the glycolytic pathway show di↵erent tendencies for PTMs
and we can localize these di↵erences to a few sites that can have potential functional
implications.
8.3 Discussion
8.3.1 Profiles of phosphorylation, acetylation and methylation of the bone
marrow-derived cells reflect functions of each cell types
Profiles of protein phosphorylation, methylation and acetylation were heterogeneous
across all cell types. Comparison of the profiles across cell types revealed that the major
di↵erence lay along the line of haematopoietic versus non-haematopoietic origin. The
PTM profiles of the haematopoietic lineage cells did not show a clear separation between
the myeloid (GRA, MON, ERP) and the lymphoid (LYM) populations. Some of the
di↵erences might be attenuated by the heterogeneity of the cell populations analyzed in
this study. All cell populations from the haematopoietic lineage were isolated through
positive selection of a cocktail of surface markers, and will include cells at various stages
of development.
One hallmark feature I observed is the preferential acetylation in the HPC population.
Previous studies have revealed that metabolic profiles of pluripotent stem cells were di↵er-
ent from their terminally di↵erentiated progenitors [Yanes et al., 2010,Panopoulos et al.,
2012]. The metabolism of pluripotent stem cells shifts from oxidative phosphorylation to
aerobic glycolysis, feature known as Warburg e↵ect characteristic of cancer cells [Panopou-
los et al., 2012,Folmes et al., 2011]. Acetate is accumulated during reprogramming of mouse
induced pluripotent stem cells, and is shown to delay early di↵erentiation in both human
and mouse embryonic stem cells [Folmes et al., 2011]. In addition, metabolic and transcrip-
tional analysis in embryonic stem cells showed that pluripotent cells produce acetyl-CoA,
the source material of acetylation, through glycolysis but the function is rapidly lost upon
di↵erentiation [Moussaie↵ et al., 2015]. Together these evidences suggested that the shift of
metabolism to glycolysis in stem cells may contribute to the observed elevated acetylation
level in HPCs.
Despite both being multiple-potent stem cell populations within the human bone mar-
row, MSCs do not show preferential acetylation of proteins. In fact, its modification pat-
terns were distinct from HPCs. The bone marrow HPCs is among the best studied adult
stem cell population in human and is defined by their potentials to regenerate and produce
all blood and immune cells throughout entire lifespan, whereas the bone marrow-derived
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non-haematopoietic MSCs are characterized as being able to replicate as undi↵erentiated
cells and also have the tri-lineage di↵erentiation capacity [Morrison et al., 1995,Mackay
et al., 1999]. It has been discussed that some of the inherent stem cell properties of the
HPCs may not be transferable to other types of adult stem cells including MSCs [Lindner
et al., 2010]. The di↵erences in the properties of HPCs and MSCs as well as their functional
di↵erences most likely explain the large di↵erences observed for each modifications in this
dataset.
8.3.2 Acetylation of hnRNP proteins regulates alternative splicing in haematopoi-
etic progenitor cells
A large fraction of proteins from the hnRNP family was discovered to be di↵erentially
modified in the human bone marrow. The hnRNP proteins are among the most abundant
nuclear proteins ubiquitous expressed at di↵erent levels in most tissues [Chaudhury et al.,
2010]. They form complexes with heterogeneous nuclear RNA (hnRNAs), and are con-
stantly being added or removed from the transcript during RNA splicing. They also facili-
tate the export of mRNA to cytoplasm and translation machinery. Acetylation of hnRNP
proteins has been reported in hnRNP A1, and more recently in hnRNP F, hnRNP C1/C2
and hnRNP L [Kim et al., 2006,Koumbadinga et al., 2015,Kim et al., 2015]. Deacetylation
of hnRNP C1/C2 and hnRNP L by SIRT1 has been demonstrated both in-vitro and in-
vivo through mass spectrometry and immunoblotting [Kim et al., 2015]. Administration
of deacetylase inhibitor trichostatin A (TSA) in hnRNP F resulted in changes of splicing,
further suggesting the function of acetylation in regulating the alternative splicing of hn-
RNP proteins [Koumbadinga et al., 2015]. Given the extensive acetylation events observed
on hnRNP proteins in primitive HPCs, it is tempting to postulate that genes targeted
by these acetylated hnRNP proteins are transcribed di↵erently upon haematopoiesis. In
fact, target genes of the hnRNP A1 and hnRNP A2B1 showed increased exon skipping
( on average 20%) in the di↵erentiated CD4+ T cells compared to undi↵erentiated HSC
(analyzed dataset from [Casero et al., 2015, Huelga et al., 2012], Supplementary Figure
10). The increased exon skipping events hinted that regulation of RNA splicing by specific
hnRNP proteins during di↵erentiation might be linked to its acetylation profile.
Besides regulating splicing activity through acetylation, modifications can also indirectly
modulate the function of hnRNPs. Modifications such as phosphorylation, sumoylation,
ubiquitination, and methylation are all known to a↵ect the stability and cellular localiza-
tion of the hnRNP proteins [Glisovic et al., 2008, Chaudhury et al., 2010,Gao G, 2017].
Acetylation of hnRNP F on the mutually exclusive acetylation and ubiquitination sites K87,
K98 and K224 are shown to be critical for the enhanced protein stability and alternative
splicing induced by the deacetylase inhibitor TSA [Koumbadinga et al., 2015]. Degradation
of hnRNP A1, hnRNP I and hnRNP L can also be prevented by TSA, further suggesting a
conserved mechanism for regulating the stability and function of hnRNP proteins through
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protein PTMs. As the results showed that a considerable amount of acetylation sites and
some methylation sites identified on hnRNP proteins were previously identified as ubiqui-
tination and SUMOylation sites, it is plausible that during haematopoiesis the dynamics of
protein abundance within the repertoire of hnRNP proteins are also regulated by di↵erent
PTM codes.
As the most common among the three RNA-binding motifs in hnRNP proteins, RRM
domain also showed di↵erential modification in the human bone marrow. The typical
RRM contains four anti-parallel  -strands and two ↵-helices, arranged in a  ↵  ↵  fold
[Dreyfuss et al., 1988]. The  -sheet surface of the RRM constitute an exposed surface
for direct interaction with RNA [Go¨rlach et al., 1992]. Specificity of RNA binding of the
hnRNP proteins is determined by loop-regions connecting the  -strands as well as the
terminal regions of the RRM [Go¨rlach et al., 1992]. A single RRM typically can interact
with 2-6 nucleotides, which is su cient for RNA binding. Multiple copies of RRM, as in the
case of several hnRNPs, can provide enhanced specificity and a nity for RNA binding, thus
allowing recognition of larger and complex RNA sequences [Maris et al., 2005]. Since the
identified modification residues in bone marrow were mostly mapped outside the  -sheets
in the loop-regions, these modifications are unlikely to interfere with the RNA binding.
However the specificity of the hnRNP proteins to their target RNA as well as the stability
and function of the hnRNP proteins may be altered upon modification. Hence, additional
in-vitro and in-vivo functional study on these identified modification sites may provide
further insights on the key residues and modifications that govern the activity of hnRNP
proteins in the human bone marrow.
Given that most of the modifications were identified in the conserved RRM domain
present in the most of the hnRNP proteins, it is very likely that the single PTM as well as
co-occurred PTMs observed in hnRNP A2B1, hnRNP A1 and hnRNP M may be conserved
across the entire family. One could suggest that there are potentially more PTMs on these
sites that are not identified in this study and could be essential for the function of hnRNP
proteins in bone marrow cells.
8.3.3 Glycolytic proteins are di↵erentially directed for sub-cellular localiza-
tion through phosphorylation and acetylation
Enzymes in the glycolysis pathways were di↵erently phosphorylated across cell types
in human bone marrow. The most frequently detected modification sites do not directly
impact on the catalytic activity of those enzymes, but in-vitro and in-vivo experiments
indicated that these PTMs may direct the cellular location of these proteins. S202 phos-
phorylation on PKM2 was consistently observed in cells from haematopoietic lineage.
AKT-directed S202p is essential for the nuclear translocation of PKM2, which is required
for STAT5A activation and IGF-induced cell growth [Park et al., 2016b]. Constitutive
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activation of STAT5A has been shown to promote human haematopoietic stem cell self-
renewal, which is in agreement with the observed high frequency of S202p in HPCs pop-
ulation [Schuringa et al., 2004]. Phosphorylation of S203 on PGK1 by ERK is required
for its mitochondrial translocation, which inhibit the mitochondrial pyruvate metabolism
and enhances glycolysis [Li et al., 2016]. For GAPDH, PKC-directed T246 phosphoryla-
tion decreases GAPDH tetramerization, reduces GAPDH glycolytic activity and inhibits
GAPDH-directed mitophagy in-vitro and ex-vivo [Yogalingam et al., 2013,Qvit et al., 2016].
High proportion of S203p on PGK1 were observed in MSC and MON, and at a comparable
frequency of T246p on GAPDH in MSC, MON, LYM and GRA. The low frequency of
phosphorylation on these two sites in HPCs and ERPs implied that the glycolysis rate in
the two cell types may be comparatively higher than in the other four cell types.
The di↵erentially regulated acetylation sites also a↵ect the localization of glycolytic en-
zymes in various ways. Acetylation directly regulates the abundance of PKM2. Enhanced
acetylation of K305 on PKM2 has been shown to prevent the tetramerization of active
enzymatic form and reduces the synthesis of pyruvate and acetyl-CoA [Park et al., 2016a].
K305 acetylation on PKM2 enhances its interaction with HSP70, which in turn increased
its uptake by lysosome, leading to degradation [Xiong and Guan, 2012]. Mutation of PKM2
on K305 further results in accumulation of several glycolytic intermediates and stimulation
of cell proliferation and growth [Lv et al., 2011]. Acetylation of K305 on PKM2 was ob-
served in all bone marrow cells, and proportionally higher in HPCs and GRAs, suggesting
that the turnover of PKM2 in bone marrow through acetylation is stronger in the two cell
types. In addition, acetylation directly regulate the subcellular localization of metabolic
enzyme GAPDH, interfering with its enzymatic and non-enzymatic functions. Cytoplasmic
GAPDH is a key enzyme in glycolysis, whereas nuclear GAPDH have many other functions
including transcriptional regulation, DNA repair, and telomere maintenance [Zheng et al.,
2003]. Acetylation of K117 on GAPDH by PCAF is required for nuclear translocation of
GAPDH [Ventura et al., 2010]. Hence the high proportion of K117 acetylation on GAPDH
in HPCs presumable plays an active role in maintaining the genomic integrity of the stem
cell population in the human bone marrow.
Taken together, the observed cell type specific acetylation and phosphorylation dif-
ferences can be linked to the localization of glycolytic proteins in the bone marrow cells.
This may indirectly regulate the catalytic and non-catalytic activities of those metabolic
proteins.
8.4 Conclusion and perspective
Proteins from the hnRNP family were preferentially acetylated in the primitive HPC
populations, which can potentially a↵ect the pattern of alternative splicing in these bone
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marrow stem cells. In addition, proteins in the glycolysis pathways are di↵erentially phos-
phorylated and acetylated, modulating their subcellular localization. The compartmen-
talization may di↵erentially regulate turn-over rate, catalytic and non-catalytic activity of
those metabolic proteins across cell types in the human bone marrow.
Further in-vitro and in-vivo experiments could be performed to verify the identified
modification sites. Of particular interest, inhibition of phosphorylation or acetylation ei-
ther with inhibitors or site-directed mutagenesis could reveal the regulatory function of the
identified modification sites on the glycolytic enzymes. Similarly, applying mutagenesis
approach on the hnRNP proteins will enable us to understand whether the identified mod-
ification sites regulate binding specificity of the RNA transcripts, activity of alternative
splicing and stability of hnRNP proteins. Alternatively, the hnRNP proteins could also be
examined using acetylation inhibitors followed by transcriptomics analysis to understand
down-stream e↵ects on di↵erent haematopoietic cell populations.
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9 Dynamics of Protein Phosphorylation, Acetylation and
Methylation As Readouts of Biological Ageing in Human
Bone Marrow
9.1 Introduction
Several studies have described age related alterations in either changes in protein
abundance or levels of PTMs such as acetylation and phosphorylation [Johnson et al.,
2013,Walther et al., 2015,Pal and Tyler, 2016]. In this study, we are able to consider both
the unmodified proteins and the modified proteins as a whole and examine their variations
with respect to age across six di↵erent bone marrow cell types. Through the combination
of standard and mass-tolerant database search method, unmodified and modified proteins
were identified. Proteins regulated by phosphorylation, acetylation and methylation were
analyzed for age related changes. We seek to define primarily, how the profiles of PTMs
change with age across di↵erent cell types, and further to understand if any biological pro-
cesses are particularly changed and might serve as potential biomarkers for ageing. The
results presented in this chapter show the age-associated dynamics of PTMs across di↵erent
types of bone marrow cells.
9.2 Result
9.2.1 Protein post-translational modifications in human bone marrow largely
remain stable during ageing
Bone marrow cells collected from 59 donors with age from 20 to 60 were analyzed using
quantitative shotgun proteomics. For every protein identified, I was able to quantitatively
measure one to two spectrum for the modified peptides in each donor using TMT isobaric
tags. This low number of quantified spectrum per modified peptides implies estimates
of modification levels at the peptide level would be more sensitive to measurement noise.
Therefore, I implemented a more robust estimate of the level of modification at the protein
level. For each modified protein, I averaged the TMT intensity across all modified peptides
and termed this PTM score. This PTM score reflects the likelihood for a protein to be
modified. When comparing two PTM scores for the same protein between two samples,
a higher PTM score indicates that the protein in one sample is more frequently modified.
However to apply statistical methods such as linear model or any other tests assuming a
normal distribution, one might not have su cient power to infer the exact modified peptide
that e↵ects this di↵erence.
With the PTM scoring method, 695 phosphorylated proteins, 258 methylated proteins
and 328 acetylated proteins were quantified across six bone marrow cell types (Figure
28A). For each modification, the proportion of proteins quantified to all modified proteins
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Figure 28: Modification levels of the modified bone marrow proteins showed cell-type specific di↵erences.
A) for the proteins identified to be phosphorylated, methylated and acetylated, the percentages of proteins
quantified based on PTM score were at comparable levels across six cell types. The numbers of phospho-
rylated proteins that can be quantified for ERPs, GRAs, HPCs, LYMs, MONs and MSCs were 178, 184,
133, 235, 278 and 437, representing 28 to 30% of the identified phosphorylated proteins. The numbers of
acetylated proteins that can be quantified for the six cell types (same order as above) were 55, 72, 143,
106, 99 and 183, representing 32 to 42% of the identified. The numbers of methylated proteins that can
be quantified for the six cell types (same order as above) were 62, 66, 42, 67, 79 and 185, representing
36 to 65% of the identified. B) principle component analysis on the PTM scores of the modified proteins
(including phosphorylated, acetylated and methylated forms) showed that a large part of the variations
across samples can be explained by cell types.
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Figure 29: Modification levels for phosphorylated and methylated proteins in the human bone marrow
remained largely stable during ageing. A) the partial correlation coe cients of phosphorylated proteins
and methylated proteins in the bone marrow were centred around 0, with median values of -0.003 and
-0.011 for phosphorylation and methylation, respectively. B) the overall distributions of partial correlation
coe cients of phosphorylated proteins and methylated proteins showed similar distribution across six bone
marrow derived cell types. The median of partial correlation coe cients were shown with box plots and
annotated below the plot. C) in MSCs the abundance of the unmodified elongation factor 2 had a slight
negative correlation with increasing age, whereas D) the PTM score of the methylated elongation factor 2
(corrected for the abundance of the unmodified) were positively correlated with age. The partial correlation
coe cient was 0.31.
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Figure 30: Modification level for the acetylated proteins in HPCs were biased towards negative correlation
with age. A) the partial correlation coe cients of acetylated proteins in the bone marrow were centred
around 0, with a median of -0.027. B) the distributions of partial correlation coe cients of acetylated
proteins across di↵erent bone marrow cells showed that the distribution in HPCs was towards a negative
correlation with age than in the other bone marrow cells. The median of partial correlation coe cients
of the six cell types were shown with box plots and annotated below. C) in HPCs the abundance of the
unmodified calreticulin showed slightly negative to no correlation with increasing age, whereas D) the PTM
score of the acetylated calreticulin (corrected for the abundance of the unmodified) were negative correlated
with age in HPCs. The partial correlation coe cient was -0.70.
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detected were comparable across six cell types. The modified proteins that can be quantified
were 28 to 30% of identified phosphorylated proteins, 32 to 42% of the acetylated proteins,
and 36 to 65% of the methylated proteins.
After quantifying the modified proteins with PTM scores, the first question I asked is
what are the factors that best describe the observed variations in the PTM scores across
all samples. Principal component analysis (PCA) on PTM scores of modified bone mar-
row proteins revealed that cell type di↵erence can explain a large part of the variation
between di↵erent samples (Figure 28B). Modified proteins in the haematopoietic and non-
haematopoietic lineages were well separated on the first component. These indicates that
there are many proteins detected more in their modified forms in MSCs as compared to
other cell types. In addition, cells from the haematopoietic lineage were clustered into
individual cell types, though cells from the lymphoid and myeloid lineage were not dis-
tinctively separated. This indicates that the modified proteins that can be quantified with
PTM scoring method was reliable and is representative for the proteome of each cell type.
When we further examining the other PC components, there were 2 components showed
significant correlation with age (unadjusted pvalue < 0.01) (Supplementary Table 1). This
suggested that there were variations associated with age across all individuals and cell
types, indicating that the quantification of modified proteins can be further analyzed for
age associated variations.
To find out the association between the level of protein modification and the biological
age of individual, one fact that needs to be accounted for is that for a given protein, its PTM
score is directly associated with the abundance of its unmodified form. The abundance of
the unmodified protein may also change during ageing. Therefore I used partial correlation
analysis to address this question. In essence, with partial correlation analysis, associations
between the PTM score to biological age and between abundance of unmodified proteins
to PTM score were first examined. Then the degree of association between PTM score
and biological age was measured while controlling for potential e↵ects of the unmodified
proteins.
For phosphorylation and methylation, we did not observe heavy tailed distributions or
shifts in the median from zero, for the partial correlation coe cients across all proteins
(Figure 29A). This implied the bone marrow proteins showed no strong consensus in terms
of increased or decreased modification with respect to age. The distributions of partial
correlation coe cients between the PTM score and age stratified by cell types further
revealed that distributions of partial correlation coe cients were similar across the six
bone marrow cell types (Figure 29B). A small proportion of proteins do have modifications
changes that are related to age. As exemplified in Figure 29C, elongation factor 2 (eEF2)
had a positive partial correlation coe cient of 0.31 in MSCs. The abundance of unmodified
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eEF2 was slightly negative correlated with increasing age in MSC populations, whereas on
the contrary the PTM score of the methylated eEF2 (after correcting for the abundance
of the unmodified) in MSCs showed a clear positive correlation with age (Figure 29D).
Acetylation showed a similar profile of its partial correlation with age as phosphory-
lation and methylation. The acetylated fraction of the bone marrow proteome displayed
no strong correlation with age (Figure 30A). However, when examining the distribution
across di↵erent cell types, the results showed a bias towards negative association in the
HPC populations (Figure 30B). This indicated that the acetylation of a large number of
proteins decreased with age in HPCs. Calreticulin was among one of the proteins with
negative association between PTM score and age. The partial correlation coe cient of
calreticulin was -0.70 in HPCs. As illustrated in Figure 30C and Figure 30D, the abun-
dance of unmodified calreticulin showed slight negative to no correlation with age in HPCs,
whereas the PTM score of the acetylated calreticulin (after correcting for the abundance
of the unmodified) displayed a clear negative correlation with age.
In conclusion, combining partial correlation analysis with PTM score revealed cell-
type specific trends in terms of PTM changes during ageing. Proteins with high partial
correlation coe cients could be potential candidates for further analysis on age-association.
9.2.2 Modified proteins in haematopoietic progenitor cells forms correlated
clusters during ageing
After assessing the association between changes of protein phosphorylation, acetylation
and methylation and age with partial correlation analysis, we asked the question whether
these changes are coordinated during ageing. In gene regulatory network analysis, genes
that show a coordinated expression pattern across numerous samples are grouped into co-
expression clusters based on correlation measures [van Dam et al., 2017]. A similar strategy
for grouping modified proteins whose abundance levels are highly similar across samples
was applied. We termed this group of modified proteins as correlated clusters.
To determine the correlated clusters of proteins, the pairwise correlation coe cients
between the modified proteins were calculated based on their PTM scores. This pairwise
correlation is calculated across all cell types and samples. Phosphorylated, acetylated and
methylated forms of the same protein were considered separately. The modified proteins
were then clustered according to their pairwise correlation coe cient to find the correlated
clusters (Figure 31A and Supplementary Figure 12). After defining groups of these coordi-
nated modified proteins independently of age, I further asked whether any of these defined
groups of modified proteins show a concerted change during ageing.
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Figure 31: Modified proteins in haematopoietic progenitor cells co-evolved during ageing. A) pairwise
correlation between modified proteins in HPCs were calculated based on their PTM scores. The modified
proteins were then clustered according to pairwise correlation coe cient using Ward’s method, and clustered
into 7 groups. B) distribution of the partial correlation coe cient between PTM scores of modified proteins
and age within each cluster in HPCs were shown. With ANOVA test, proteins belong to group 2, 4 and
7 were found to have significantly di↵erent distributions of partial correlation coe cient from the others
after multiple testing adjustment with Bonferroni correction. C) interaction network of proteins belonged
to the second group of co-evolved proteins in HPCs. Protein-protein interaction network was built using
STRING. For each protein, its partial correlation coe cient between PTM scores and age were annotated
in bracket.
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Table 3: Modification sites di↵erentially regulated during ageing
Protein Site Modification Partial Correlation Coe cient p. adj
14-3-3 protein beta/alpha T32 Acetylation -0.42 0.042
Methionine–tRNA ligase Y410 Phosphorylation 0.30 0.079
Clathrin Y169 Phosphorylation -0.55 0.079
SEC22b S137 Phosphorylation -0.56 0.079
The degree of similarity between modified proteins showed various patterns across dif-
ferent bone marrow cell types. The distribution of partial correlation coe cients between
cluster showed di↵erences in the HPC population (Supplementary Table 2). The distribu-
tion of partial correlation coe cients between the PTM score and age for modified proteins
within each cluster in HPCs were shown in Figure 31B. Overall proteins belonging to cluster
1, 2, 3, 5 and 6 were mostly negatively associated with increasing age (with median partial
correlation coe cient from -0.21 to -0.023) , whereas proteins in group 4 and 7 were mostly
positively associated during ageing (median partial correlation coe cient 0.036 and 0.16).
Proteins belonging to 2,4 and 7 clusters were found to have significantly di↵erent distribu-
tions of their partial correlation coe cient from proteins in the other groups (adjusted p
value < 0.05).
We further asked whether there are any known interactions in the clusters that showed
overall association with age. Network analysis was performed on proteins belonging cluster
2, 4 and 7. Proteins belonging to cluster 2 and 4 had significantly more interactions than
the number of interactions expected at the genome level (Figure 31C and Supplementary
Figure 13). Proteins in cluster 4 were mostly mediated by phosphorylation, whereas all
three modifications were found in modified proteins in cluster 2. There were 17 modified
proteins in cluster 2 that formed interaction networks, including RNA binding proteins
such as hnRNP A1, hnRNP D and elongation factor 1-↵1 (EEF1A1), structural component
of the cell such as myosin (MYH9), actin (ACTG1, ACTB) and filamin-A (FLNA), and
variants of histone H1 (HIST1H1C, HIST1H1B and HIST1H1E). Modifications on these
proteins were mostly negatively correlated with age, further suggesting that these modified
proteins may participate in processes that are co-operatively suppressed in the process of
ageing.
9.2.3 Di↵erential regulation of site-specific modifications in bone marrow dur-
ing ageing
We attempted to elucidate whether there are any site-specific modifications that changes
with age using partial correlation method. As mentioned above, the estimate of the re-
lationship between age and modified peptide abundance comes with large errors due to
the low number of quantified spectrum per modified peptides. To circumvent this and to
increase statistical power, I combined measurements across cell types to enable a more
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accurate estimate of the relationship between age and modified peptide abundance. We
have stronger evidence of a relationship between abundance of modified peptide and age
if an age-related e↵ect is consistently observed across more than one cell type. To analyse
the degree of association between modification frequency at a modification site (the abun-
dance of the specific peptide with modification) and biological age, the potential e↵ect of
the unmodified was controlled using partial correlation analysis.
In total 547 modified peptides were analysed, including 303 phosphorylated peptides,
98 methylated and 146 acetylated. The distribution of the partial correlation coe cients of
those modified suggested that the majority of the modification sites were not significantly
altered during ageing. After adjusting for multiple testing using Benjamini-Hochberg, four
peptides were found to be di↵erentially modified during ageing (Table 3). However, no
functional information is known about modifications on these sites.
9.3 Discussion
9.3.1 Abundance of modified proteins in bone marrow derived cells shows
cell-type dependencies and correlations with age
We observed a bias towards negative correlation between frequency of acetylation
and age in HPCs. This may be attributed to the altered pluripotency in the aged stem
cell populations. Bone marrow haematopoietic stem cells are known to have high sus-
ceptibility to age-related changes such as skewed di↵erentiation potential [Morrison et al.,
1995,Wahlestedt et al., 2017]. Perturbation of global acetylation can a↵ect stemness of
cells. For example, studies on embryonic stem cell showed that the di↵erentiation of stem
cell can be delayed through using inhibitors upstream of acetyl-CoA [Moussaie↵ et al.,
2015]. In addition, over-expression of deacetylase SIRT2 in human pluripotent stem cells
(hPSCs) also a↵ect stem cell functions including di↵erentiation capacity [Cha et al., 2017].
Therefore, the decreased amount of acetylated proteins in HPCs was in good agreement
with previous observations.
Although levels of modification for most modified bone marrow proteins were relatively
stable during ageing, there were individual proteins observed to have strong correlations
with age across di↵erent cell types. For example, the abundance of methylated eEF2
was positively correlated with increasing age in MSC population. Function of eEF2 is
positively regulated by longevity- promoting rapamycin through inhibition of eukaryotic
elongation factor 2 kinase (eEF2K) [Redpath et al., 1996,Proud, 2015]. Hence, one might
hypothesize that the increased eEF2 methylation in MSC upon ageing is associated with
its diminishing activity. There are few studies on the mechanism of eEF2 methylation,
but one possible mediator of this methylation - eEF2 activity relationship would be FGF
signalling [Jung et al., 2011]. The fibroblast growth factors (FGFs) are important regulators
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for the development of bone from MSCs and methylation of eEF2 was shown to be induced
by basic fibroblast growth factor (bFGF) through MAPK signalling pathway in mouse
embryo fibroblast NIH3T3 cells [Jung et al., 2011,Coutu et al., 2011]. The exact functional
consequence of eEF2 methylation needs to be clarified with further experiments.
9.3.2 Changes of modification levels on histone H1 variants may modulate
chromatin structure in bone marrow haematopoietic progenitor cells
during ageing
We were able to infer clusters of modified proteins in HPCs that are highly coordinated
in terms of modification frequency, which might be a result of common regulatory pathways
during ageing. Three variants of histone H1, namely H1.2 (HIST1H1C), H1.4 (HIST1H1E)
and H1.5 (HIST1H1B) were correlated through phosphorylation and acetylation. There
are 7 human histone H1 isoforms ubiquitously expressed in somatic cells. H1.1, H1.2,
H1.3, H1.4 and H1.5 are expressed during replication, and H1.x and H1.0 are expressed
throughout the cell cycle [Izzo and Schneider, 2016]. H1 histones are linker proteins that
binds to the entry and exit sites of DNA on the surface of nucleosomal core particles.
They are dynamic components of chromatin and are required for the stability of chromatin
structure [Hergeth and Schneider, 2015]. Like other histone proteins, H1 histones were
found to carry di↵erent modifications. Phosphorylation and acetylation of histone H1
variants have been observed in regions where directly involved in DNA binding and are
known to a↵ect DNA condensation capacity of H1 proteins [Talasz et al., 2009,Wi´sniewski
et al., 2007,Roque et al., 2008,Hergeth and Schneider, 2015].
We observed negative correlations between levels of phosphorylation of histone H1.2
and H1.4 and age in HPCs. One possible explanation would be that during ageing, the
phosphorylation level on histone H1 in HPCs, especially H1.4 decreases, reducing the com-
paction of chromatin and contributing to immunosenescence. Recent studies on mRNA
expression and mouse model have suggested that individual H1 variants play significant
roles in embryonic stem (ES) cell di↵erentiation [Terme et al., 2011,Zhang et al., 2012]. In
pluripotent human NTERA-2/D1 (NT2) cells and mouse ES cells the levels of H1.4S187
phosphorylation and H1.2/H1.5S173 phosphorylation decrease globally during di↵erenti-
ation [Liao and Mizzen, 2017]. Furthermore, in human peripheral blood lymphocytes, it
has been observed that the phosphorylation of H1.4 and H1.5 is significantly decreased
with increasing age, contributing to an increase in senescence-associated heterochromatin
formation [Happel et al., 2008]. All these evidences substantiate a potential link between
histone H1 phosphorylation and reduced di↵erentiation potential in bone marrow HPCs
during ageing.
In addition to phosphorylation, the decreased level of acetylation on histone H1.5 may
also impact the chromatin compaction, potentially a↵ecting di↵erentiation and prolifera-
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tion potential of the HPCs during ageing. In di↵erentiated human ES cells, histone H1.5
is shown to bind preferentially to genes encoding membrane and membrane-related pro-
teins [Li et al., 2012]. Binding of H1.5 is associated with gene repression and is required for
chromatin compaction, whereas depletion of H1.5 resulted in increased chromatin accessi-
bility, deregulation of gene expression, and decreased cell growth. There are few studies
on histone H1.5 acetylation, but functions of acetylation have been analyzed on the other
histone H1 variant H1.4. Acetylation of H1.4 is known to activate transcription by di-
rectly reducing H1 a nity to chromatin and by recruiting subunit of the transcription fac-
tor [Kamieniarz et al., 2012,Terme et al., 2014]. One could hypothesise that the decreased
acetylation of histone H1.5 may follow a similar mechanism, disrupting the maintenance of
condensed chromatin and selectively a↵ecting transcription of a subset of genes, but this
remains to be elucidated in future studies.
9.4 Conclusion and perspective
At the level of the entire bone marrow proteome, the levels of phosphorylation, acety-
lation and methylation on the bone marrow proteins remained relatively stable during
ageing. A small proportion of modified proteins displayed age-associated changes on mod-
ification frequencies, but no specific pathways enriched for these specific modified proteins
were observed. Of note, the HPC populations showed a bias towards negative association
between acetylation level and age, which may correlate with its altered pluripotency. We
also observed that the coordinated modification patterns of histone H1 variants. The de-
creased levels of phosphorylation and acetylation may have an impact on the chromatin
structure, contributing to immunosenescent features in the elderly population .
As the results of this study recovered only a part of the entire modified bone marrow
proteome, the number of modification sites that allows detection of significant associations
with age is rather limited. Nonetheless it is reasonable to believe that there are potentially
more proteins di↵erentially modified at specific modification sites upon ageing, which alter
the functions of the proteins and ultimately contribute to the age-associated senescence
of the immune system. Further studies with targeted approaches, focus on particular cell
types (e.g HPC) and increased number of samples can increase the power greatly, and yield
more significant results to help to uncover the correlation between protein modification and
ageing in the human bone marrow.
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10 Conclusion and Perspectives
The human bone marrow proteome was represented by six main sub-populations of
cells and quantitatively measured by shotgun proteomics. The combination of standard
and mass-tolerant database search methods e↵ectively identified abundant PTMs in the
bone marrow and quantified bone marrow proteins with those abundant modifications.
The bone marrow proteins were extensively modified. The modification profiles of
phosphorylation, acetylation and methylation were cell-type dependent, with distinct sep-
aration between cells from the haematopoietic and non-haematopoietic lineages. Proteins
di↵erentially modified across cell types regulate a diverse spectrum of processes inside the
bone marrow, including glucose metabolism and alternative splicing.
On top of cell type di↵erences in PTMs, this study allowed us to examine changes of
the human bone marrow proteome across timespan of 40 years. Modification level for the
majority of the modified proteins in bone marrow remained stable during ageing. In the
HPC populations a negative association between acetylation level and age was observed,
which may be linked to diminished di↵erentiation potential of the stem cells during ageing.
Taken together, these results suggest that post-translational modification patterns can
inform us of the di↵erences in pathway regulation across cell types, and also have the
potential to serve as either biological markers of the ageing processor indications of di↵erent
pathway activities during ageing.
As the modified proteins identified in this study only represented a partial image of
the entire modification landscape of the human bone marrow proteome, one can anticipate
that further studies with more elaborate study designs can deepen our insight on the
importance of PTMs in bone marrow during ageing. Targeted approaches will allow us
to survey more broadly the dynamics of protein modifications across cell types. Apart
from further complementary experiments to confirm the functions of these modification
during ageing, one can also envision the application and development of computational
strategies to model and predict the degree of ageing in an individual, based on integrating
post translational profiles with other genetic and phenotypic information, for example, gene
expression and epigenetic changes.
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11 Material and Method
11.1 Sample collection
Cells were collected from donated bone marrow (donor age between 20 and 69) at Hei-
delberg University Hospital under the approval by the ethics committee. Bone marrow as-
pirates from the iliac crest of healthy human subjects were washed with phosphate-bu↵ered
saline (Sigma-Aldrich) and transferred to Ficoll-Paque (15 mL, Biochrom). Mononuclear
cells (MNCs) were obtained through centrifugation at 800g for 30 min. For cell-type-specific
internal standards, MNCs were collected from umbillical cord blood using the same proce-
dure. Cells from the five cell types from haematopoietic lineage,namely monocyte progen-
itor cells (MONs, CD34-, CD14+, CD45+), granulocyte progenitor cells (GRAs, CD34-,
CD14-, CD45+, high Ssc-a), lymphocyte progenitor cells (LYMs, CD34-, CD14-, CD45+,
low Ssc-a), erythroid progenitor cells (ERPs, CD34-, CD14-, CD45-) and haematopoietic
progenitor cells (HPCs, CD34+) were isolated by fluorescence-activated cell sorting (FACS)
using haematopoietic lineage marker antibodies and side-scattered light index accordingly.
The bone marrow mesenchymal stromal cells were obtained through in vitro culture of
MNCs. The MNCs were seeded in fibronectincoated culture flasks (75 cm2) with a density
of ⇡100 cells/mL in Verfaillie medium till adherent colonies were formed. MSCs were then
scraped from the culture flask. All cells were stored at -20 C before lysis.
11.2 Cell lysis
The quantity of cells used for each donor in the analysis is cell-type dependent due to the
di↵erences in the protein concentrations across di↵erent cell types and sample availability.
For each donor, 1.105 of HPCs, 1.106 of ERPs, 5.105 of LYMs, MONs, GRAs and MSCs
were used. Frozen cell pallets were lysed in HEPES bu↵er (200mM HEPES, PH 8) con-
taining 1% protease inhibitor cocktail (Sigma-Aldrich) and 0.5% RapiGest SF (Waters).
Cell lysate were incubated at 90 C for 5 min, followed by 20 min sonication and 5 min cen-
trifugation with 16,000g to precipiate DNA and cell debris. Proteins were collected from
supernatant layer and incubated with 2mM dithiothreitol (Sigma-Aldrich) at 23 C for 30
min with 300 rpm. The denatured proteins were then reacted with 5mM iodoacetamide
(Sigma-Aldrich) in dark for 30 min, and then quenched by 5 min UV-exposure with natural
light. The reduced and alkylated protein mixtures were firstly digested by Lys-C enzyme
(1:1000 (w/w), 0.01µg/µl Lys-C in HEPES bu↵er, Wako) for 3 hours at 37 C, followed by
digestion with trypsin (1: 500 (w/w), 0.01µg/µl, in 1% (v/v) trypsin resuspension bu↵er)
for 16 hours at 37 C.
11.3 Peptide labelling and separation
Digested peptides were labeled with TMT-6plex isobaric mass tags (Thermo) according
to the manufacturer’s instructions. Cell-type specific internal standards were labelled with
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TMT channel 126, whereas the samples from donors were randomized for their age and
labelled with TMT channel 127 to TMT channel 131. 20µl of TMT (0.02mg/µl in acetoni-
trile) was directly added to the digested peptide mixture and reacted at 23 C for 1 hour
with 300 rpm. The reaction was terminated by incubation with 5% (v/v) hydroxylamine
at 23 C for 15 min with 300 rpm. 10% (v/v) trifluoroacetic acid was added to the labelled
mixture to condition the bu↵er to PH below 3. The mixture was incubated for 45 min at
37 C with 300 rpm to cleave the acid-labile structure on RapiGest, and centrifuged for 20
min at 4 C with 16,000 g to pallet the insoluble part of RapiGest. TMT-labelled peptide
was collected from supernatant and desalted on SepPak C18 column. SepPak column was
first equilibrated with 1ml elution bu↵er (0.6% (v/v) acetic acid in 80% (v/v) acetonitrile),
and 1ml washing bu↵er (0.6% (v/v) acetic acid). Peptide mixture was conditioned with
additional 500 µl washing bu↵er and loaded to the equilibrated SepPak column, washed
with 1ml washing bu↵er and eluted with 500µl elution bu↵er. Eulate from each TMT
channel were concentrated in speed vacuum concentrator to 50 µl and adjusted to PH >7
using 2 M sodium hydroxide (Sigma-Aldrich).Subsequently the eluate were labelled again
using same amount of TMT of the same channel, using aforementioned procedure. The
double-labelled samples were concentrated to 50 µl, washed using SepPak column following
the same procedures and eluated with 500 µl elution bu↵er.
To determine the labelling e ciency, 25 µl eluate from each TMT channel were com-
bined, concentrated in vacuum concentrator, protonated with 1% formic acid and analyzed
by Q Exactive mass spectrometer (Thermo Scientific). Ratio among TMT channels were
obtained by analyzing data using Proteome Discoverer (version 1.4.1.14, Thermo Fisher
Scientific). If the results shows that any of the samples have over 2 fold deviation from
the mean of the ratio across all six TMT channel, a second check were performed prepared
based on the value obtained from the first mixture. After the mixing ratios were adjusted
within 2 fold deviation from the mean of the ratio across all six TMT channel, samples
were concentrate to 50 µl for peptide separation.
11.4 Reversed-phase chromatography separation of the TMT-labeled
peptides
The concentrated peptide mixture was fractionated using reversed-phase liquid chro-
matography (Agilent 1260 infinity HPLC system) with equipped with XBridge C18 reversed-
phase column (3,5 µm 1 x 100 mm, Waters). Fractions were concentrated and desalted
using Oasis HLB µElution Plate. Plate was equilibrated with 200 µl elution bu↵er, followed
by flushing with 200 µl washing bu↵er. Peptide mixture was conditioned with additional
100 µl washing bu↵er and loaded onto plate. Fractions were combined to 18 samples as
shown in Supplementary Figure 14. Peptides were washed with 200 µl washing bu↵er and
eluated with 50 µl elution bu↵er. All fractions were concentrated to less than 10 µl and
protonated with 1% formic acid for LC-MS/MS analysis.
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11.5 Nano reversed-phase chromatography tandem mass spectrometry
The fractions were analyzed on LTQ Orbitrap Velos Prof mass spectrometer (Thermo)
equipped with nanoAquity UPLC flow column (Waters) and Proxeon nanospray source
(Proxeon Biosystems) connected. Each fraction was separated on C18 column. The HPLC
eluate was directly electrosprayed into the mass spectrometer. Full scan spectra, from 300
m/z to 1,700 m/z at resolution of 30,000 (profile mode) were acquired in the Orbitrap mass
analyzer. Ions with 10 highest intensities from the full scan MS were selected for fragmen-
tation in the ion trap. Only multiply charged (2+, 3+) precursor ions were selected for
MS/MS. The dynamic exclusion list was restricted to 500 entries with maximum retention
period of 30s and relative mass window of 10 ppm.
11.6 Database search
To check the TMT labelling e ciency, MS/MS spectra were searched against the Uniprot
human database using Proteome Discoverer (version 1.4.1.14, Thermo) and MASCOT
search engine (Matrix Science). The following search parameters were used: peptide mass
tolerance at +/- 20 ppm, MS/MS tolerance at 0.1 Da, trypsin enzyme with up to 2 missed
cleavages, fixed modification of TMT 6-plex (lysine), TMT 6-plex (N-term), variable mod-
ification of methionine oxidation and cysteine carbamidomethylation, and a reverse decoy
database pattern. All reported data were based on 95% confidence levels for protein and
peptide identification as determined by the false discovery rate (FDR) of no more than 1%;
All identified proteins were filtered for with at least one unique peptide.
For identification of unmodified proteins and proteins with modifications, ProteoWiz-
ard was used to convert mass spectrometry data from Thermo raw file format to mzML
format. All MS/MS spectra assignments were performed using Comet software (version
”2016.01 rev. 2”) against Uniprot human database. Decoy database was constructed by
reversing sequences from Uniprot human database. The database search parameters were
as follows: trypsin was selected as the enzyme; a maximum of two missed cleavages were
allowed; precursor ion tolerance (MS1 search window) was set to 15 ppm; fragment ion bin
tolerance was 0.02; cysteine carbamidomethylation (+57.021464 Da), methionine oxidation
(+15.9949 Da), lysine and peptide N-terminal TMT-6plex tagging (+229.1629 Da) were se-
lected as dynamic modifications. When performing search for proteins with modifications,
the modifications of interests were added to the dynamic modification search parameter;
for each file 20 CPU were used for spectra assignment, which took approximately 20 to
40 min. For identification of potential modifications, search parameters were the same
as for identification of unmodified proteins with a few di↵erences: maximally five missed
cleavages were allowed; precursor ion tolerances were set to 100 Da, 200 Da, 300 Da, 400
Da and 500 Da; for each file 40 CPU were used for spectra assignment. Depending on the
precursor ion tolerance, the database search for one file may take up to 8 -12 hours.
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A protein was accepted as being identified when the following criteria were all fulfilled:
1) for single spectrum to sequence assignment, the assignment was the best match by
Comet. 2) at least 3 unique peptides were detected for the same protein. 3) passed 1%
false discovery rate at protein level.
11.7 Protein and peptide quantification
Intensity values of reporter ions were extracted from raw data using Bioconductor R
package ”mzR”. The reference molecular weight of TMT tags used were 126.2193 Da for
TMT126, 127.2127 Da for TMT127, 128.2046 Da for TMT128, 129.1981 Da for TMT129,
130.1900 Da for TMT130 and 131.1834 Da for TMT131. When obtaining intensity values
from raw data, the mass value between two TMT channels were used to separate signal
from di↵erent TMT channels. Intensity values of one TMT channel was accepted only
when the values are above the median intensity value of all spectra obtained within the
same scan. The intensity of one TMT channel of one scan were the sum of all intensity
values of spectra that passed the median cuto↵.
For quantification of proteins, all 18 fractions from one pool were consolidated. Only
proteins with more than 2 unique peptides were used for quantification. The abundance of
each protein is estimated by taking the mean intensities of all its PSMs. Modified protein
abundance were estimated separately from unmodified proteins, for example, abundance
of modified phosphorylated protein A was estimated using only phosphorylated peptides
found in protein A. After obtaining estimates of abundance for all proteins in each sample,
the protein abundance for each sample was normalized by taking the log2 value, followed
by scale function in R (center around its mean and scaled by standard deviation).
11.8 Mass shift peak picking
For identification of mass shift peaks, spectra which has no peptide matching during
identification of unmodified peptides and has a matching in searches for potential modifi-
cations were kept, whereas any conflicting spectra, i.e. spectra identified in both searches
for unmodified peptides and modified peptides were discarded. For each spectra, mass shift
was calculated by subtracting the experimentally acquired mass value by its predicted the-
oretical mass value. Gaussian kernel function was applied to calculate the density of the
mass shifts. Mass shifts were partitioned into discrete bins, with a bandwidth of 0.0025.
Second derivatives of density of each bin was calculated. Local maxima of the second
derivatives were called out as mass shift peaks. We estimated the background signal as
the mean of the density of those non-empty bins, and used 1.5 of the mean as the cuto↵
to select the mass shift peaks that above background. Peak picking was performed for all
open search results from 100Da to 500Da.
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11.9 Deduction of PTM from mass shift
Protein PTMs were deduced from comparing the molecular weight of known protein
PTMs in Unimod database with the mass of the mass shift peaks. Mass shift peaks iden-
tified from all mass-tolerant searches were checked for whether the mass shift values of
the identified mass shift peaks match to the molecular weight of any known protein PTMs
would induce on peptide. The mono-isotopic masses of modifications annotated in protein
modification database Unimod were used as reference. Peptides with mass shift values
within the range of 0.01 Da from molecular weight of any known modifications in Unimod
database were collected and considered as candidates. Furthermore, for the peptides under
the mass shift peaks that have a match to a modification to Unimod database, the frequen-
cies amino acids were calculated. A Fisher's exact test was applied to to determine whether
there is any enrichment of animo acids (p <0.05). A modification was considered to be
present in the dataset only if the enriched amino acids correspond to the ones required for
the matched Unimod modification. Modifications inferred from all mass tolerant search
results from all six cell types were combined.
11.10 Cross-checking modified peptides in PhosphoSitePlus Database
Peptides identified with phosphorylation from the standard search including phospho-
rylation as dynamic search parameter were collected and compared with phosphorylated
peptides annotated in PhosphoSitePlus database (version 03-21-2017). For the reference
peptides, phosphorylated peptides in PhosphoSitePlus, both the peptides annotated to
have been identified in high-throughput and low-throughput studies were chosen. A phos-
phopeptide was considered as verified if the same modification site has been identified in
previous studies. Similarly, acetylated peptides and methylated peptides identified from the
standard searches were compared against the acetylated peptides and methylated peptides
annotated in PhosphoSitePlus database.
11.11 Gene Ontology enrichment
Bioconductor R package ”biomaRt” was used for mapping protein identity to the cor-
responding Gene Ontology indeitity. The Gene Ontology (GO) data from homo sapiens
was used for enrichment analysis. For enriched GO terms, a Benjamini-Hochberg (0.01%)
was applied to address the multiple testing issue.
11.12 Enrichment of protein domains for modified peptides
Unmodified, phosphorylated, methylated and acetylated peptides were mapped to Inter-
Pro database to retrieve information on the corresponding protein domains. Occurrence of
each peptide in each cell type was calculated. A Fisher's exact test followed by Benjamini-
Hochberg (0.01%) was applied to the ratios of occurrence for each protein domain in the
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modified to the unmodified to determine the enrichment of protein domains in the modified
proteins.
11.13 Frequencies of amino acids flanking modification site
We extracted the sequences flanking the modification site, using 10 amino acids in both
directions. For each of the 20 amino acids, we tested at each position (-10 to +10 of the
modification site), whether the frequency of the particular amino acid at the particular
position is di↵erent from its frequency across all other positions. A two -sided Fisher test
is used to determine the significance of the enrichment. We converted the p values from the
fisher test using a  log10 transformation. The transformed log10 p values were assigned
a positive value if the amino acid is enriched, and a negative value if the amino acid is
depleted.
11.14 Peptide sequence and phosphopeptide motif enrichment
Phosphorylated peptides were extracted from the data and visualized for phospho-
peptide motif using pLogo [O’shea et al., 2013]. Peptide motif enrichment analysis was
performed using MEME [Bailey et al., 2009]. The Uniprot human database was used to
calculate background amino acid distribution. We restricted to search motif with minimum
length of 6 amino acids to maximum length of 10 amino acids.
11.15 Identification of PTM hotspot
A protein PTM hotspot was defined as a 15 amino acid sequence on protein with more
than 3 detected modification sites. Phosphorylated, acetylated and methylated peptides
were counted for calculating PTM hotspot. All modified peptides that were within 3 amino
acids of another peptide were collapsed into one group. The most common peptide within
a group was used to represent the group. Proteins identified with PTM hotspots were
clustered according to the types of modifications within the hotspot using binary function.
11.16 Distribution of phosphorylation frequency around other PTMs
For each protein, I calculated for each phosphorylation site, the nearest distance to
each type of PTM that reside on the same protein (for example methylation). Then I
can classified each phosphorylation site based on this distance, for example, whether it
is 10 amino acids, 20 amino acids or other amino acids acid distances (in steps of 10
amino acids) away from its closest PTM of interest. I also calculated the total number of
phosphorylated peptides harbouring each phosphorylation site. Using the classification and
the phosphorylated number as a proxy for phosphorylation frequency, I estimated at each
distance, the proportion of phosphorylation that were detected at this distance. Confidence
interval for this proportion were estimated using the binomial proportion interval.
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11.17 Reactome pathway enrichment
Bioconductor R package ”ReactomePA” was used for mapping modified proteins to
pathways annotated Reactome database. All proteins identified in the bone marrow were
taken as background to determine the phosphorylated, acetylated and methylated pro-
teins are significantly enriched in a pathway. The p value obtained for each pathway was
corrected for multiple testing using Benjamini-Hochberg. A final FDR cuto↵ of 0.05 was
applied.
11.18 Cell-type specific heterogeneity of modification sites
All modified peptides that were within 3 amino acids of another peptide were collapsed
into one group and represented by the most common one within the group. For a given
protein, the di↵erence across all modification sites detected in six cell types were compared
using Chi-square based test with simulated p value. Only proteins with at least 5 modified
peptides in at least two cell types for each modification were analyzed. Benjamini-Hochberg
was used to address multiple testing. A final FDR cuto↵ of 0.05 was applied.
11.19 Identification of di↵erentially modified proteins in bone marrow
For a given protein, frequency of modification was estimated as the ratio of its modified
peptide count to the unmodified peptide count. For each modified protein, the di↵erences
of the modification status was compared using frequency of modification across cell types
using an extension of Fisher’s exact test, followed by multiple testing correction with
Benjamini-Hochberg (FDR < 0.05). Only proteins with at least 10 unmodified peptides
and 3 modified peptides for each modification were analyzed.
11.20 Comparison of modification frequency of proteins in glycolysis
pathway
Proteins involved in glycolytic pathway were extracted from ReactomePA database.
Assuming that for each modification, each potential modified residue on proteins within the
glycolytic pathway has the same probability of being modified, the total number of peptides
for a given protein was counted (adjusting for protein abundance), and multiplied by the
total number of modifiable residues per peptide (adjusting for number of modification sites).
The resultant number is the total expected modification sites for the given protein. Scaling
factor for this protein thus can be calculated by diving the total expected modification
sites of the protein by the mean of the expected modifications sites for all proteins in the
glycolytic pathway. To determine whether there is any cell-type preference for modifications
(i.e. more dominant in one cell type than the others) for individual protein in the pathway,
for each protein and each modification, the number of its modified forms was normalised by
the total amount of its protein forms (both modified and unmodified). A binomial test was
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applied with the null hypothesis that for each modification, the modification rate of the
same protein was the same among all six cell types. Proteins were then filtered for with at
least one modified peptides being detected in any of the 6 cell types. Because all proteins
within the glycolytic pathways were tested for cell-type preference for each modification,
Benjamini-Hochberg method was applied to address for multiple comparison and the final
adjusted p values were obtained.
11.21 Structural visualisation and analysis
Protein structures were assembled using software MacPymol (version v1.7.4.5; Schrodinger,
LLC). Crystal structures and NMR structures of the hnRNP proteins were downloaded
from PDB database.
11.22 Imputation of missing values in modified proteins
Modified proteins from acetylation, phosphorylation, methylation and deamidation were
used. Use of deamidation is to facilitate more accurate normalization of samples. The
protein abundance values for all these proteins are normalized in each sample (as described
above) and used for imputation using the R package missForest. The maximum iteration
was set to 100 and the final imputation value was taken after convergence of the algorithm.
11.23 Clustering of modified proteins
The full protein abundance values for methylated, acetylated and phosphorylated pro-
teins, containing imputed values (from above) was used to calculate pairwise spearman
correlation. Hierachical clustering using the ward.D method was performed on the pair-
wise spearman correlation matrix, and clusters were defined by using the cutree function
in R, defining the number of clusters.
11.24 Partial correlation of proteins abundance with age
Abundance of modified and unmodified proteins were corrected for pool e↵ects using
a linear mixed model that includes age as fixed e↵ect and pool as random e↵ect. Spear-
man partial correlation between age and modified protein abundance was calculated, while
controlling for the influence of unmodified protein abundance.
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12 Supplementary
Supplementary Table 1: Top 10 principle components most correlated with age












Supplementary Table 2: Di↵erences in partial correlation coe cients between clusters across six cell types
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Supplementary Figure 1: Sample purify of fluorescence-activated cell sorting. Purity of all samples sepa-
rated through FACS were indicated with colours from red (70%) to blue (100%). (this figure is from my
collaborator Ximing Ding)
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Supplementary Figure 2: Validation of modified peptide with protein modification database. Dehydrated
and oixidised phophorylated peptides, dehydrated phosphorylated peptides and di-methylated peptides were
compared to peptide entires annotated in curated protein phorsphorylation and methylation database. The
percentages of peptides matching to a database entry were 67% to 79%, 62% to 83% and 55% to 77%,
respectively. The peptide matching rates were at least 1.5 higher than the background (indicated by the
red dashed lines).
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Supplementary Figure 3: Comparison between spectrum identified with 2-amino-3-oxo-butanoic acid mod-
ification and with oxidised and dehydrated phosphorylation. For data from one MS fraction, with standard
database search include 2-amino-3-oxo-butanoic acid as dynamic modification parameter, one obtained 5623
PSM. For the same result file, with standard database search include dehydation and oxidation as dynamic
modification parameter, one obtained 4739 PSM. 2783 spectrum had shared identifications between the two
modification.
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Supplementary Figure 4: Proteins co-regulated by phosphorylation, methylation and acetylation across six
cell types were enriched in various pathways in human bone marrow.
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Supplementary Figure 5: Sequences of hnRNP A2B1 are highly conserved across multiple species. Species
analysed include human (P22626), rat (A7VJC2), mouse (O88569), bovine (Q2HJ60), cotton-top tamarin
(Q9TTV2), and sumatran orangutan (Q5RBU8).
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Supplementary Figure 6: RRM domain of hnRNP A1 are conserved across multiple species. Species
analyzed include human (P04256), chimpanzee (A5A6H4), rhesus macaque (Q28521), mouse(P49312), rat
(P04256), bovine (P09867), and african clawed frog (P17130).
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Supplementary Figure 7: RRM domain of hnRNP C are conserved across multiple species. Species ana-
lyzed include human (P07910), mouse (Q9Z204), rat (G3V9R8), chimpanzee (A5A6H4), rhesus macaque
(Q28521), rabbit (O77768), and african clawed frog (P19600).
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Supplementary Figure 8: hnRNP A2B1 and hnRNPA1 showed cell-type dependent preferences for phos-
phorylation and acetylation sites across di↵erent bone marrow cells. Dominant modification sites were
di↵erent across di↵erent cell types. For acetylation site on hnRNP A2B1, T123 was the most dominantly
acetylated site in MSCs, MONs, GRAs and ERPs, whereas T176 is more frequently acetylated in LYMs
and HPCs. S29 was most frequently phosphorylated on hnRNP A2B1 in MSCs where as in MONs, LYMs,
HPCs Y135 is the preferred phosphorylation site. For hnRNP A1, S158 was the preferred phosphorylation
site in MSCs, MONs and ERPs, whereas Y1228 was most frequently detected in HPC and LYMs.
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Supplementary Figure 9: Structures of RRM domains of hnRNP H1, hnRNP A1 and hnRNP M. NMR
structure of N-terminal RRM domain of hnRNP H1(PDB: 2lxu), X-ray crystal structure of RRM domains
of hnRNP A1(PDB:1l3k) as well as NMR structure of the second and third RRM domain of hnRNP M
(PDB:2do0) with detected modification sites were shown. Acetylation site was coloured in green, phospho-
rylation in cyan, methylation in orange. Site with multiple modification detected was shown in red, which
were S22 on hnRNP A1 for phosphorylation and acetylation, and K239 in hnRNP M for acetylation and
methylation.
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Supplementary Figure 10: Alternative splicing events of hnRNP protein-associated transcripts. Transcripts
associated with hnRNP A1 and hnRNP A1B1 in human 293T cells were obtained from [Huelga et al., 2012].
RNA expressed in CD 4+ and HSC cells were obtained from [Casero et al., 2015].The targets of hnRNP
A1 and hnRNP A2B1 in CD 4+ T cells showed a bias of exon skipping in HSC.
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Supplementary Figure 11: Proteins regulating fructose metabolism within the glycolysis pathway were
more frequently modified. For each cell type, all proteins associated with glycolytic pathway was analysed
for their modification frequency. All modifications (including oxidation and deamidation) were taken into
consideration. Assuming that for each modification the corresponding modification residues on each protein
within the pathway have the same probability of being modified, the number of the modified peptides were
normalised by the total number of peptides detected for a given protein and the number of residues that
can be modified for the protein. From the normalized modified peptide counts, it can be seen that for each
cell types, protein modifications were more frequent in fructose metabolism within the glycolysis pathway.
The glycolytic pathway was illustrated on the left panel, and the normalized modified peptide counts were
shown on the right panel, with di↵erentially phosphorylated and acetylated proteins highlighted in red.
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Supplementary Figure 12: Pairwise-correlation between modified proteins in di↵erent bone marrow cells.
The correlations were calculated based on PTM scores. Modified proteins in ERPs, LYMs, MONs, GRAs
and MSCs co-evolved and can be further clustered into di↵erent groups.
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Supplementary Figure 13: Protein-protein interaction between modified proteins in haematopoietic progen-
itor cells. Proteins in cluster 4 in HPCs from clustering analysis were mostly mediated by phosphorylation.
The relationship between phosphorylation level and age for these proteins were heterogeneous as 9 were
positively related with age and 7 were negatively related with age.
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Supplementary Figure 14: Fractionation scheme for orthogonal liquid-chromatography separation. Samples
were labelled with TMT 6plex and combined. The concentrated peptide mixture was fractionated using
reversed-phase liquid chromatography to 90 fractions. Fraction 1-82 were further combined according to
the scheme into 18 fractions.
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All the world's a stage,
And all the men and women merely players;
They have their exits and their entrances,
And one man in his time plays many parts,
His acts being seven ages. At first, the infant
Mewling and puking in the nurse's arms.
Then the whining schoolboy, with his satchel
And shining morning face, creeping like snail
Unwillingly to school. And then the lover,
Sighing like furnace, with a woeful ballad
Made to his mistress' eyebrow.Then a soldier,
Full of strange oaths and bearded like the pard,
Jealous in honour, sudden and quick in quarrel,
Seeking the bubble reputation
Even in the cannon's mouth. And then the justice,
In fair round belly with good capon lined,
With eyes severe and beard of formal cut,
Full of wise saws and modern instances
And so he plays his part. The sixth age shifts
Into the lean and slippered pantaloon,
With spectacles on nose and pouch on side;
His youthful hose, well saved, a world too wide
For his shrunk shank, and his big manly voice,
Turning again toward childish treble, pipes
And whistles in his sound. Last scene of all,
That ends this strange eventful history,
Is second childishness and mere oblivion,
Sans teeth, sans eyes, sans taste, sans everything.
As You Like It, Act II, Scene VII . W. Shakespear
